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ABSTRACT
Adult bronchial asthma (hereinafter, asthma) is characterized by chronic airway inflammation, reversible airway
narrowing, and airway hyperresponsiveness. Long-standing asthma induces airway remodeling to cause an in-
tractable asthma. The number of patients with asthma has increased, while the number of patients who die
from asthma has decreased (1.7 per 100,000 patients in 2009). The aim of asthma treatment is to enable pa-
tients with asthma to lead a healthy life without any symptoms. A partnership between physicians and patients
is indispensable for appropriate treatment. Long-term management with agents and elimination of causes and
risk factors are fundamental to asthma treatment. Four steps in pharmacotherapy differentiate mild to intensive
treatments; each step includes an appropriate daily dose of an inhaled corticosteroid (ICS), varying from low to
high doses. Long-acting β2 agonists (LABA), leukotriene receptor antagonists, and theophylline sustained-
release preparation are recommended as concomitant drugs, while anti-IgE antibody therapy is a new choice
for the most severe and persistent asthma. Inhaled β2 agonists, aminophylline, corticosteroids, adrenaline, oxy-
gen therapy, etc., are used as needed against acute exacerbations. Allergic rhinitis, chronic obstructive pulmo-
nary disease (COPD), aspirin induced asthma, pregnancy, and cough variant asthma are also important factors
that need to be considered.
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1. AIM OF MANAGEMENT, DEFINITION, DIS-
EASE TYPE, DIAGNOSIS AND SEVERITY OF
ASTHMA
1.1. DEFINITION AND PATHOLOGY OF ASTHMA
Adult bronchial asthma (hereinafter, asthma) is char-
acterized by repetitive cough, wheezing, dyspnea, re-
versible airway narrowing, and airway hyperrespon-
siveness. Asthma symptoms tend to be more severe
in more hyperresponsive airways. Airways hyperre-
sponsiveness is not always associated with asthma
symptoms. Asthma is characterized by chronic air-
way inflammation accompanied by the infiltration of
eosinophils, lymphocytes, mast cells, etc., and the de-
tachment of the airway epithelial cells.1,2 While many
patients carry IgE antibodies against environmental
allergens, airway inflammation and lymphocyte acti-
vation are noted even in patients without allergen spe-
cific IgE antibody. The clinical picture of asthma is
multifactorial, thus, different clinical pictures of
asthma have attracted attention. Some patients suffer
from airway inflammation with predominating neutro-
phils. Patients with long-standing asthma suffer from
airway remodeling, consisting of subepithelial fibro-
sis under the basement membrane, smooth muscle
hypertrophy, and submucosal gland hyperplasia,
which results in intractable asthma with irreversible
airflow limitation and persistent airway hyperrespon-
siveness.3 In the elderly, clinical picture of asthma
may be complicated by coexisting chronic obstructive
pulmonary disease (COPD).
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Table　1　Aims of asthma treatment
1. Lead a normal and healthy life. Maintain normal growth.
2. Maintain normal respiratory function.
PEF variation is in a range of <20% of predicted value.
PEF is ≥80% of predicted value.
3. Allow sufficient night sleep without cough or dyspnea at night or in the early morning.
4. Prevent asthma attacks.
5. Avoid death from asthma.
6. Prevent adverse effects caused by therapeutic agents.
7. Prevent the development of irreversible airway remodeling.
Table　2　Diseases that should be differentiated from asthma
1. Upper respiratory tract diseases: laryngitis, epiglottitis, vocal cord dysfunction (VCD)
2. Proximal respiratory tract diseases: endotracheal tumor, foreign body aspiration, tracheomalacia, endobronchial tuberculosis,
sarcoidosis
3. Diseases from the bronchus to alveolar regions: COPD, diffuse panbronchiolitis, pulmonary fi brosis, hypersensitivity pneumo-
nitis
4. Cardiovascular diseases: congestive heart failure, pulmonary thromboembolism
5. Cough caused by medicines, such as ACE inhibitors
6. Other causes: spontaneous pneumothorax, vagotonic effects, hyperventilation syndrome, and psychogenic cough
7. Allergic respiratory diseases: allergic bronchopulmonary aspergillosis, allergic granulomatous angitis (Churg-Strauss syn-
drome), eosinophilic pneumonia
Table　3　Important features for diagnosis of adult asthma
1. Paroxysmal dyspnea, wheezing, repeated cough (particularly at night and in the early morning)
2. Reversible airfl ow limitation: Response to treatment. Diurnal variation in the PEF rate is ≥20%. Forced expiratory volume in 
one second (FEV1) is increased by ≥12% and ≥200 mL in absolute volume by β2 agonist inhalation
3. Airway hyperresponsiveness: Measurement of airway contractility to acetylcholine, histamine, and methacholine
4. Atopy: IgE antibodies against environmental allergens
5. Airway infl ammation: Increased eosinophils in sputum and peripheral blood, high ECP, Creola bodies, increased fraction of 
exhaled nitric oxide (FeNO)
6. Differential diagnosis: Exclude diseases caused by other cardiopulmonary disorders
1.2. AIM OF THE MANAGEMENT AND TREAT-
MENT OF ASTHMA (Table 1)
Our aim is to alleviate and ameliorate airway hyperre-
sponsiveness and airflow limitation by eliminating the
inducers of airway inflammation and airflow limita-
tion, by suppressing inflammation by pharmacother-
apy, and by dilating the constricted airway. Respira-
tory function is normalized as much as possible to im-
prove patients’ quality of life (QOL) and enable them
to lead a normal and healthy life.
1.3. DIAGNOSIS OF ADULT ASTHMA
Diagnosing mild asthma with neither wheezing nor
dyspnea is often difficult. Delayed diagnosis may
cause chronic severe asthma. Generally, clinical diag-
nosis of asthma is based on (i) repetitive symptoms,
such as paroxysmal dyspnea, wheezing, chest tight-
ness and cough, (ii) reversible airflow limitation, and
(iii) exclusion of other cardiopulmonary diseases (Ta-
ble 2). Its diagnostic criteria has not been estab-
lished. Instead, “signs” suggestive of asthma are
shown in Table 3.
1.3.1. Recurrence of Paroxysmal Dyspnea,
Wheezing, Chest Tightness, and Cough (often
develop at night and in the early morning)
Asthma is characterized in repeated exacerbation
that occur amid symptom-free intervals and develop
even during rest. Patients with asthma may feel dysp-
nea (choking) during exercise and laborious work.
Asthma with such symptoms, occurring within the
past 12 months, is called current asthma. The histo-
ries of (i) development and persistence of dyspnea,
(ii) emergency room visits and hospitalization due to
paroxysmal dyspnea, (iii) improvement of symptoms
when using an anti-asthmatic drug, and (iv) dyspnea
caused by exposure to certain causative substances
support the diagnosis of asthma.
Adult Asthma
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Table　4　Classifi cation of asthma severity based on clinical fi ndings before treatment (adults)
Severity† Mild intermittent Mild persistent Moderate persis-tent Severe persistent
Features of 
asthma 
symptoms
Frequency Less than once a week
Once or more a 
week, not every 
day
Every day Every day
Intensity
Mild and brief
Disturb everyday 
life and sleep 
once or more a 
month
Disturb everyday 
life and sleep 
once or more a 
week
Restrict everyday 
life
Short-acting 
inhaled β2 agonist 
is needed almost 
every day
Frequently exacer-
bated under treat-
ment
Symptoms at 
night
Less than twice a 
month
Twice or more a 
month
Once or more a 
week Frequently
PEF
FEV1‡
%FEV1, %PEF ≥80% ≥80% ≥60%, <80% <60%
Variation <20% 20-30% >30% >30%
†Determine the severity based on the presence of any one of the symptoms.
‡In patients with severe or long-standing symptoms, severity may be underestimated when determined based on symptoms. Respiratory
function indicates the objective severity of airway obstruction. Its variation is associated with airway hyperresponsiveness. %FEV1, (FEV1 
measured value/FEV1 predicted value) × 100; %PEF, (PEF measured value/PEF predicted value or the best value) × 100.
1.3.2. Reversible Airflow Limitation4
Wheezing and dyspnea during attacks are caused by
reversible airway narrowing, which develops exten-
sively in the airway, with the peak expiratory flow
(PEF) and forced expiratory volume in one second
(FEV1) altered markedly from exacerbation to stabili-
zation periods. Asthma-specific alterations in PEF and
FEV1 have not been established, but 20% diurnal
variation in the PEF suggests asthma. Reversible air-
flow limitation is regarded as significant when FEV1
is increased by 12% and 200 mL in an absolute
volume after β2 agonist inhalation. If the increase is
below that level after β2 agonist inhalation, reversibil-
ity may be detectable after oral corticosteroid admini-
stration for 2-3 weeks. In addition, even if no signifi-
cant difference is noted in respiratory function tests
before and after β2 agonist inhalation, asthma is still
suspected when there is a significant difference
(20%) between the PEF rates before using a bron-
chodilator in the early morning and those after inhal-
ing a β2 agonist between 12: 00 pm and 14: 00 pm.
1.3.3. Airway Hyperresponsiveness5,6
The airway is contracted by stimuli to which healthy
individuals show no response. A standard quantita-
tion method of the Japanese Society of Allergology or
an astograph method can be used. In the former
method, a patient inhales a bronchoconstrictor (e.g.,
acetylcholine, methacholine, or histamine) for 2 min
for the assessment of airway hyperresponsiveness us-
ing PC20 (i.e., a concentration to reduce FEV1 by 20%)
and PD20 (i.e., a cumulative dose during that time). In
the latter method, a patient inhales methacholine of
different concentrations. Airway hyperresponsiveness
is assessed as Dmin, the concentration of meth-
acholine at which airway resistance starts increasing.
Both methods are load tests that include induction of
airway narrowing, thus, caution should be taken for
patients with decreased respiratory function. Baseline
%FEV1 (percentage of FEV1 against a predicted
value) is desirably70%.
1.3.4. Atopic State
Specific IgE antibodies against various environmental
allergens indicate atopic state.
1.3.5. Exclusion of Diseases to Be Differentiated
A comprehensive diagnosis should be made if bound-
ary regions of asthma-like symptoms, caused by
other cardiopulmonary diseases, or coexisting
asthma need to be considered (Table 2).
1.3.6. Airway Inflammation
Increased percentages of eosinophils, high ECP
(eosinophil cationic protein) value, and Creola bodies
comprised of exfoliated airway epithelial cells, de-
tected by sputum examination, indicate allergic air-
way inflammation.7 Increased fraction of exhaled ni-
tric oxide (FeNO) also suggests airway inflamma-
tion.8,9 An increased number of eosinophils in the pe-
ripheral blood and elevated serum ECP values also
Ohta K et al.
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Table　5　Treatment steps for asthma
Treatment step 1 Treatment step 2 Treatment step 3 Treatment step 4
Long-term 
management 
agents
Basic 
treatment
Inhaled corticoste-
roid (low dose)
Inhaled corticoste-
roid (low to medium 
doses)
Inhaled corticoste-
roid (medium to 
high doses)
Inhaled corticosteroid
(high dose)
If the above agent 
cannot be used, 
use one of the fol-
lowing agents.
・LTRA
・Theophylline sus-
tained-release 
preparation
(unnecessary for 
rare symptoms) 
If the above agent 
is ineffective, con-
comitantly use one 
of the following 
agents.
・LABA
(a compounding 
agent can be 
used)
・LTRA
・Theophylline sus-
tained-release 
preparation
Concomitantly use 
one or more of the 
agents below.
・LABA
(a compounding 
agent can be 
used)
・LTRA
・Theophylline sus-
tained-release 
preparation
Concomitantly use 
multiple agents of  
those below.
・LABA
(a compounding 
agent can be used)
・LTRA
・Theophylline sus-
tained-release prep-
aration
If poorly controlled 
with all of the above 
agents, add either 
or both of the agents 
below.
・Anti-IgE antibody‡
・Oral corticosteroid§
Additional 
treatment
Antiallergics other 
than LTRA†
Antiallergics other 
than LTRA†
Antiallergics other 
than LTRA†
Antiallergics other 
than LTRA†
Exacerbation treatment¶ Inhaled SABA Inhaled SABA Inhaled SABA Inhaled SABA
LTRA, leukotriene receptor antagonists; LABA, long-acting β2 agonist; SABA, short-acting β2 agonist.
†Antiallergics refer to mediator antireleasers, histamine H1 antagonists, thromboxane A2 inhibitors, and Th2 cytokine inhibitors.
‡Anti-IgE antibody is indicated for patients who are positive for perennial inhaled allergen with serum total IgE value of 30-700 IU/mL.
§Oral corticosteroids are intermittent administration for a short period. Keep the minimum maintenance dose if a patient cannot be con-
trolled by enhanced treatment with other agents and short intermittent administration.
¶Management against mild exacerbations are shown. For other exacerbations, refer to Table 23.
suggest airway inflammation.
Of the above “signs,” (1.3.1.) respiratory symp-
toms, (1.3.2.) reversible airflow limitation, and (1.3.5.)
asthma symptoms not caused by other cardiopulmon-
ary diseases are diagnostically important. If the respi-
ratory function is normal, the presence of (1.3.3.) air-
way hyperresponsiveness and (1.3.6.) allergic airway
inflammation support a diagnosis of asthma.
1.4. CLASSIFICATION OF ASTHMA SEVERITY
AND EXACERBATION INTENSITY
Assessment of asthma severity and exacerbation in-
tensity is important for the management of asthma,
and is fundamental to stepwise pharmacotherapy (Ta-
ble 4). The initial treatment is selected from treat-
ment steps 1 to 4 (Table 5) according to the severity
of asthma (Table 4); i.e. step 1 for mild intermittent,
step 2 for mild persistent, step 3 for moderate persis-
tent and step 4 for severe persistent (see Table 5,
“Treatment steps for asthma”). To achieve the aim of
asthma treatment (Table 1), the present controlled
status should be maintained (see Table 18, P17). The
symptoms and the present treatment step determine
a treatment strategy, such as strengthened treatment
in the same step or step-up for one or two steps (Ta-
ble 6). If asthmatic symptoms are controlled for 3-6
months, step-down of treatment can be attempted.
Exacerbation intensity in asthma is classified in Table
7.
1.5. INTRACTABLE ASTHMA
Intractable asthma is one of the most severe and per-
sistent types of asthma, with daily development of
symptoms, even when treatment step 4 in Table 5, ex-
cept for oral corticosteroid and anti-IgE antibody, is
conducted. Additional potential underlying diseases
such as aspirin induced asthma, Churg-Strauss syn-
drome and other systemic vasculitis syndrome, and
allergic bronchopulmonary aspergillosis should be
considered in asthma patients requiring continuous
oral corticosteroid administration.
2. EPIDEMIOLOGY OF ASTHMA
2.1. CHANGES IN ASTHMA PREVALENCE OVER
TIME
Asthma prevalence has been rapidly increasing in re-
cent years. An International Study of Asthma and Al-
lergies in Childhood (ISAAC) survey was conducted
Adult Asthma
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Table　6　Classifi cation of asthma severity based on the present treatment (adults)
Present treatment step
Patient’s symptoms in the present 
treatment Treatment step 1 Treatment step 2 Treatment step 3 Treatment step 4
Controlled†
Mild intermittent Mild persistent Moderate persis-tent Severe persistent・No symptoms
・No symptoms at night
Mild intermittent‡
Mild intermittent Mild persistent Moderate persis-tent Severe persistent
・Less than once a week
・Mild and brief
・Less than twice a month at night
Mild persistent§
Mild persistent Moderate persis-tent Severe persistent Severe persistent
・Once or more a week, not every 
day
・Once or more a month, disturbs 
everyday life and sleep
・Twice or more a month at night
Moderate persistent§
Moderate persis-
tent Severe persistent Severe persistent
Most severe persis-
tent
・Every day
・Requires short-acting inhaled β2 
agonist almost every day
・Once or more a week, disturbs 
everyday life and sleep
・Once or more a week at night
Severe persistent§
Severe persistent Severe persistent Severe persistent Most severe persis-tent
・Frequently exacerbated even un-
der treatment
・Every day
・Restrict everyday life
・Frequently at night
†Consider step-down after continued treatment for 3-6 months.
‡Enhance treatment at each step.
§Check compliance with treatment, and consider step-up as needed.
in Fukuoka City and Tochigi Prefecture and across
Japan to examine the prevalence of asthma at specific
time points (Table 8). Asthma prevalence at different
areas cannot be precisely compared between years,
because it markedly varies with regions. However,
the mean prevalence in Japan was estimated to have
increased from about 1% to 6% in children and from
<1% to about 3% in adults since the 1960s. In addition,
according to a survey conducted over several years,
in which the same physicians used the same protocol
in subjects with the same background (Table 9),10,11 a
1.5-2-fold increase was reported every 10 years, both
in Japan and overseas (Fig. 1). In a survey of adult
asthma in citizens of Fujieda City, Shizuoka Prefec-
ture conducted in 1986 and 1999, the prevalence of
asthma increased from 3.14% to 4.15%.
2.2. REGIONAL DIFFERENCES IN ASTHMA
PREVALENCE
The ISAAC Steering Committee reported regional dif-
ferences in the cumulative prevalence of asthma in
13-14-year-old subjects, at 155 sites, in 56 countries in
the world, ranging from 1.6% in Indonesia to 36.8% in
UK (Fig. 2). The prevalence in Japan was comparable
with or slightly lower than prevalence in Europe and
USA (e.g. Fukuoka City, 13%, Tochigi Prefecture,
19%). A comparison of the European Community Res-
piratory Health Survey (ECRHS) and studies in Japan
showed that the prevalence in Japan was lower
(8.1%), although the surveys were conducted in dif-
ferent years (Table 10).12
2.3. MALE-FEMALE RATIO
The prevalence of asthma is more common in males
at an early age in all the countries, however, after pu-
berty, the prevalence is more common in females. At
onset of asthma, the male-female ratios in Japan were
2.8 during infancy, 1.5 during childhood, and below
1.0 after 10 years of age. Among the elderly, females
are more likely to have asthma, but since males ac-
Ohta K et al.
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Table　7　Classifi cation of asthma symptoms and exacerbation severity (adults)
Exacerbation 
severity† Dyspnea Exertion
Laboratory data§
%PEF SpO2 PaO2 PaCO2
Wheezing/chest 
tightness
Dyspnea when in 
a hurry
Dyspnea when 
moving
Almost normal
≥80% ≥96% Normal <45 mmHg
Mild (mild exacer-
bation)
Dyspnea but no 
trouble with lying 
down
Slight dyspnea
Moderate (moder-
ate exacerbation)
Dyspnea with 
trouble with lying 
down
Difficulty in 
moving
Difficulty in 
walking
60-80% 91-95% >60 mmHg <45 mmHg
Severe (severe ex-
acerbation) 
Dyspnea, cannot 
move
Abasia
Difficulty in speak-
ing
<60% ≤90% ≤60 mmHg ≥45 mmHg
Serious‡
Respiratory insuf-
fi ciency
Cyanosis
Respiratory arrest
Anepia
Akinesia
Confusion, impaired 
consciousness, 
incontinence
Immeasurable ≤90% ≤60 mmHg ≥45 mmHg
†Determine exacerbation severity based on the extent of dyspnea, referring to other items. If symptoms of different exacerbation intensi-
ties coexist, use more severe one.
‡Perform emergency assessment against more serious symptoms, such as respiratory attenuation or arrest, anepia, impaired conscious-
ness, and incontinence.
§Refer to measured values after bronchodilator administration.
Table　8　Prevalence of bronchial asthma I
ISAAC phase I 
study in 1994
ISAAC phase I 
study in 1994
ISAAC phase III 
study in 2003
Study Group of the Ministry 
of Health, Labour and 
Welfare in 2005
Fukuoka Prefecture Tochigi Prefecture Fukuoka Prefecture Japan
6-7 years of age 17.3% 18.2% 13.9%
13-14 years of age 13.4% 19% 13.0%  8.8%
count for a lower percentage of the general popula-
tion of the elderly, we cannot conclude that the preva-
lence is led in elderly males. The male-female ratios
tend to be slightly higher in rural areas and slightly
lower in urban areas.
2.4. NUMBER OF PATIENT VISITS AND CON-
SULTATION RATE
According to the statistics of the Ministry of Health,
Labour, and Welfare (formerly Ministry of Health and
Welfare), the number of patients with asthma, who
had continued to visit a hospital until the survey date
in October 1996, which calculated hospitalized pa-
tients + new outpatients + second visit outpatients ×
average visit interval × survey coefficient, was
1,146,000 (619,000 males and 527,000 females) (Sta-
tistical Information, Ministry of Health and Welfare,
1998). In a large-scale telephone survey, conducted in
2000, the percentage of patients who received treat-
ment, calculated with the number of persons in the
screening cooperating households (126,758) and the
number of patients with asthma (1,786), was about
1.4%. Thus, the number of patients with asthma, who
received treatment, was estimated to be about
1,780,000.11
2.5. DEATHS FROM ASTHMA13
According to the Vital Statistics of the Ministry of
Health, Labour and Welfare, the number of patients
(of all ages) who died from asthma has gradually de-
creased in recent years. That stopped decreasing at a
rate of 4.5-5.0 per 100,000 patients around 1975, tran-
siently increased in 1995, decreased again after 1997,
and then hit its lowest point of 1.7 per 100,000 pa-
Adult Asthma
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Fig.　1　Changes over years in the prevalence of bronchial asthma in Japanese 
elementary school students reported by four investigators.
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Table　9　Prevalence of bronchial asthma II
1960 1970 1980 1990 2000 Ages of subjects
Fukuoka City 5.7% (81-3) 7.7% (93-5) 6-12y†
Oslo 2.2% (81) 4.2% (93) School children‡
3.4% 8.0% §
Western Japan 3.2% (82) 4.6% (92) 6.5% (02) 6-12y†
Kitakyushu 1.6% (71) 3.6% (81) 5.4% (91) 6-12y†
Aberdeen 10% (64) 20% (89) 7y¶
4.2% 10.4% ‖
South Wales
17% (73)
6%
22% (88)
12%
7y¶
‖
Australia
21.0% (87)
5.6% (87)
25.1% (90)
8.0% (90)
Adults¶
#
(  ): Year of the survey.
†current asthma (ATS-DLD), ‡current asthma (diagnosed asthma), §cumulated asthma (diagnosed asthma), ¶wheezing,
‖ cumulative asthma (diagnosed asthma), #current asthma.
tients (2,139 deaths) in 2009. In particular, the num-
ber of patients who died from asthma at an early age
markedly decreased, thus, currently 88% of deaths oc-
cur among the elderly, aged 65 years or older.
3. PATIENTS EDUCATION AND A PART-
NERSHIP BETWEEN PHYSICIANS AND PA-
TIENTS
3.1. EDUCATIONAL NEEDS
It is required for patients to have a certain amount of
knowledge in order to achieve a partnership with
medical professionals and to become capable of self-
management. Sufficient patient education regarding
asthma reduces the prevalence and mortality of
asthma, increases the patients’ QOL, and is effective
in reducing medical expenses.14 Patients who re-
ceived self-management training from a specialist in
asthma can understand severity objectively by PEF
measurements, recognize symptoms relating with
asthmatic exacerbation, and take immediate and ap-
propriate actions against attacks. Furthermore, they
can appreciate agents used periodically for long-term
management and those used as needed for control-
ling attacks. Effective education of patients includes
the provision of a written self-management plan (ac-
tion plan) that details issues related to severity, self-
management, and self-assessment, directions for use
of medications, and timing of administration.14
3.2. SUBJECTS
Education should be provided to patients, their fami-
lies, neighbors, and caretakers for the elderly.
Ohta K et al.
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Fig.　2　Allergic asthma symptoms within 1 year based on ISAAC questionnaire (ISAAC phase I study). The sur-
vey was conducted in 1995 by ISAAC (International Study of Asthma and Allergies in Childhood) in Fukuoka, Ja-
pan. Circles show the prevalence at various survey spots. An average of 3,000 persons was included for each 
spot.
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Table　10　Prevalence and period of asthma by ECRHS survey
Country Year Age Period prevalence (%)
Japan 05 20-44  8.1
Australia 92-93 20-44 28.1
Australia
Aborigine 90-91 20-84 11.1
UK 92-93
20-44 27.0
20-44 30.3
Germany 92-93 20-44 17.0
Spain 92-93 20-44 22.0
France 92-93 20-44 14.4
USA 92-93 20-44 25.7
Italy 92-93 20-44  9.5
Iceland 92-93 20-44 18.0
Greece 92-93 20-44 16.0
3.3. CONTENTS
Since asthma is a chronic disease, the needs of long-
term management must be explained. Patients, physi-
cians, and medical staffs should exchange informa-
tion to discuss expected effects and anxiety regarding
treatment. In addition, the explanation items in Table
11 should be discussed with patients. Peak expiratory
flow (PEF) meters (Table 12) with measurement in-
structions (Fig. 3) and predicted PEF standard values
and the importance of PEF measurement (Table 13)
are shown. Physicians should instruct patients on the
concepts of prophylactic treatment and review the
self-management plan with the patient (Fig. 4) if
asthma gets worse.
3.4. EDUCATORS
Aside from specialists in asthma, non-specialists such
as nurses, public health nurses, and pharmacists
Adult Asthma
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Table　11　Physician’s explanation to patients with asthma
- Diagnosis
- Differences between reliever agents and controller agents
- How to use an inhaler
- Instructions for prophylaxes
- Signs of asthma exacerbation
- PEF monitoring
- Methods and intervals of medical examination
- Self-management plan based on instructions
Table　12　Outline of PEF meters
Trade name MiniLight Assess Personal Best Vitalograph(Asmaplan)
Measuring range (L/min)
Children 30-400 Children 35-385 Children 50-390 Children 25-300
Adults 60-800 Adults 60-880 Adults 60-810 Adults 50-800
Weight (g)
Children 52
65 85 74
Adults    80
Photos
Features (written in package insert)
World’s fi rst com-
mercialized PEF 
meter. Most com-
monly used in the 
world including 
Europe.
Zone manage-
ment system 
provided by zone 
clip.
Portable storage 
case-integrated 
type. Simple 
design for storage. 
Equipped with 
zone pointer.
Equipped with mov-
able color zone.
Distributor Matsuyoshi & Co., Ltd.
Polytex
Chest
Polytex
Chest
Takara Tsusho Co.,
Ltd.
should participate in education, as community-driven
education is desired. In addition, patients’ associa-
tions, patient support groups, etc., should be included
so that they can take charge of medical education for
citizens and patients.
3.5. PLACES FOR EDUCATION
Education is provided through events held by special-
ized institutions, health centers, patient support
groups, and through distribution of various teaching
materials. Ideally, personnel training for patient edu-
cation should continue.
In Japan, information providing groups, such as the
Independent Administrative Institution, Environ-
mental Restoration and Conservation Agency of Ja-
pan ( http:www.erca.go.jpasthma2index.html) ,
the Japan Allergy Foundation (http:www.jaanet.
org), and the Japan Council for Quality Health Care
(http:minds.jcqhc.or.jpindex.aspx) all conduct
various educational activities.
4. ASTHMA MEDICATIONS
4.1. ASTHMA MEDICATION PLAN FOR THE
LONG-TERM MANAGEMENT OF ADULT ASTHMA
4.1.1. Agents
Asthma medications are divided into 2 types; long-
term management agents used continuously for long-
term management (controllers) and reliever agents
used for a short period to treat asthma symptoms (re-
lievers).
(1) Agents for long-term management (control-
lers)
Agents to alleviate and eliminate asthma symptoms,
and normalize and maintain the conditions are called
controllers. They are classified based on their mecha-
nisms of action (Table 14).
a) Corticosteroids (steroids): Steroids are currently
the most effective antiinflammatory agents for asthma
treatment.15 Important mechanisms of action include
(i) inhibiting infiltration of inflammatory cells into the
lungs and airway16 and inhibiting the migration and
activation of inflammatory cells, (ii) reducing vascular
permeability, (iii) suppressing airway secretion, (iv)
inhibiting airway hyperresponsiveness, (v) inhibiting
cytokine production, (vi) promoting the effects of β2
agonists,17 and (vii) inhibiting arachidonic acid me-
tabolism in cells other than human mast cells and the
production of leukotrienes and prostaglandins. Four
forms of steroid are available, for intravenous, intra-
muscular, oral, and inhaled use. Those used for long-
term management of asthma are usually inhaled cor-
ticosteroids. An oral corticosteroid should only be
chosen when management could not be achieved
Ohta K et al.
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Fig.　3　PEF measurement.
(1) Measure PEF in a standing position (record 
posture if standing is impossible). 
(5) Read the scale.
(2) Set the indicator of PEF meter to the zero 
or bottom of a scale.
(6) Measure similarly twice more.
(3) Inhale as deeply as possible, and put a 
mouthpiece into the mouth (prevent air leak).
(7) Record the highest value of the 3 measure-
ments in an asthma and peak expiratory flow 
diary.
(4) Exhale as quickly as possible (no need of 
exhaling all the air).
Clean the PEF meter: Wash the mouthpiece 
at least once a day in water. When the meter 
become tainted (at least once a month), 
immerse it in a dishwashing detergent for 
about 30 min, rinse it in water, and wipe 
waterdrops, followed by air drying (at least 
once a month). Avoid immersion in boiling 
water or drying with a drier to prevent 
deformity. Please see a package insert for 
details. 
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Fig.　4　Self-management plan.
Green zone: 
%PEF is 80-100%.
Maintain in this status.
Normal life can be led. 
No symptoms are noted at night.
Self-management plan
Name:
Daily medication From attending physician
Yellow zone: 
%PEF is 50-80%. 
Implement this action plan. 
Symptoms are noted at night.
Reliever agent(s) From attending physician
Red zone: 
%PEF is <50%
Emergency! 
Inform people around you 
about your ill condition. 
Immediately visit a hospital.
Agents used 
in the course
to the hospital
From attending physician
Attending physician:Hospital:
Table　13　Signifi cance of PEF monitoring
1. Alteration in airway obstruction can be followed over time.
2. Detect acute exacerbation and their therapeutic effects can be evaluated.
3. Airway obstruction can be found earlier when neither subjective nor objective symptoms are noted.
4. Diurnal variation in severity can be assessed.
5. Specifi c antigens and inducers can be elucidated.
6. The effectiveness and appropriateness of long-term treatment can be evaluated.
7. Children with asthma voluntarily participate in treatment, thereby facilitating patient education.
8. Communication between children with asthma and physicians is facilitated.
when inhaled corticosteroids were used to the great-
est extent. An aqueous suspension of triamcinolone
acetonide for intramuscular injection should not be
used because of its adverse effects.
Inhaled corticosteroids (i) reduce asthma symp-
toms, (ii) improve QOL and respiratory function, (iii)
alleviate airway hyperresponsiveness,18 (iv) inhibit
airway inflammation, (v) improve the frequency and
intensity of acute exacerbation,19 (vi) reduce the
maintenance dose of inhaled corticosteroids for a
long period of time (vii) reduce the medical expenses
for asthma, (viii) inhibit airway remodeling, and (ix)
reduce deaths from asthma. Furthermore, after the
development of asthma symptoms, early administra-
tion of an inhaled corticosteroid (early intervention)
will decrease the frequency of the acute exacerbation
of asthma.20 However, asthma cannot be cured by the
treatment and cannot be controlled if the treatment is
discontinued.18 In addition, poor compliance with in-
haled corticosteroid administration increases emer-
gency room visits and frequency of hospitalization
due to exacerbation of asthma.
In treatment step 4 for severe asthma, oral corti-
costeroids are used as long-term management agents
to complement inhaled corticosteroids, supplement
adrenocortical functions, and inhibit increases in sys-
temic inflammatory cells and inflammatory sub-
stances. However, oral corticosteroids are used for
short-term intermittent administration, or are used in
a minimum maintenance dose when continuous ad-
ministration is inevitable.
As shown in Table 15, inhaled corticosteroids, com-
mercially available in Japan in 2011, include flutica-
sone propionate (FP), budesonide (BUD), beclo-
methasone dipropionate (BDP), ciclesonide (CIC),
and mometasone furoate (MF). FP, BUD, and MF
are also available as dry power inhaler (DPI). On the
other hand, pressurized metered dose inhalers
(pMDI) using hydrofluoroalkane (HFA) as a base are
used for FP, BDP, and CIC administration. The mean
particle sizes of these agents are 6 μm > FP-DPI > FP-
HFA > BUD-DPI > MF-DPI > CIC-HFA = BDP-HFA >
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Table　14　Controllers (agents for long-term management)
1. Corticosteroids 4. Leukotriene receptor antagonists
1) Inhaled corticosteroids i) Pranlukast hydrate
i) Beclomethasone dipropionate ii) Zafi rlukast
ii) Fluticasone propionate iii) Montelukast sodium
iii) Budesonide 5. Theophylline sustained-release preparation
iv) Ciclesonide 6. Anti-IgE antibody
v) Mometasone furoate Omalizumab
2) Oral corticosteroids
2. Long-acting β2 agonists
1) Inhalants
Salmeterol xinafoate
2) Patch
Tulobuterol
3) Oral medicines
Procaterol hydrochloride
Clenbuterol hydrochloride
Formoterol fumarate
Tulobuterol hydrochloride
Mabuterol hydrochloride
3. Combination inhaler of corticosteroid/long-acting β2 agonist
1) Combination inhaler of fl uticasone propionate/salmeterol 
xinafoate
2) Combination inhaler of budesonide/formoterol
7. Antiallergics other than leukotriene receptor antagonists
1) Mediator antireleasers
Sodium cromoglicate, tranilast, amlexanox, repirinast, 
ibudilast, tazanolast, and pemirolast potassium
2) Histamine H1 receptor antagonists
Ketotifen fumarate, azelastine hydrochloride, oxatomide, 
mequitazine, and epinastine hydrochloride
3) Thromboxane inhibitors
i) Thromboxane-A2 synthesis inhibitor
Ozagrel hydrochloride
ii) Thromboxane A2 receptor antagonist
Seratrodast
4) Th2 cytokine inhibitor
Suplatast tosilate
8. Other agents and therapies (Chinese medicines, specifi c 
immunotherapy, and non-specifi c immunotherapy)
Table　15　Device for inhaled corticosteroids
pMDI
 (Pressurized metered dose inhaler)
DPI
 (Dry powder inhaler)
BDP (beclomethasone dipropionate) BDP-HFA (Qvar®) None
FP (fl uticasone propionate) FP-HFA (Flutide® Air) FP-DPI (Flutide
® Diskus, Flutide® 
Diskhaler)
Combination inhaler with SM (sal-
meterol xinafoate) FP/SM HFA (Adoair
® aerosol) FP/SM DPI (Adoair® Diskus)
BUD (budesonide) None BUD-DPI (Pulmicort® Turbuhaler)
Combination inhaler with FM (for-
moterol fumarate hydrate) None BUD/FM (Symbicort
® Turbuhaler)
CIC (ciclesonide) CIC-HFA (Alvesco®) None
MF (mometasone furoate) None MF-DPI (Asmanex® Twisthaler)
1 μm. These agents are extensively dispersed in the
airway, with smaller particles reaching further into
the peripheral airway.21 In addition, budesonide inha-
lation suspension (BIS), inhaled using a nebulizer,
was recently introduced as a new formulation. A jet
nebulizer is recommended for BIS inhalation, but an
ultrasonic nebulizer is unsuitable. To prevent adverse
effects caused by BIS inhalation, agents attached to
the face should be wiped off, and gargling and water
intake are important.
The dosages of inhaled corticosteroids are classi-
fied into a high dose (the highest dose covered by
health insurance), medium dose (half of the high
dose), and low dose (half of the medium dose) (Table
16).
Inhaled corticosteroids are effective even in rela-
tively low doses (e.g., 200 μg FP) in adults. But if in-
halation volume is increased over the high dose, fur-
ther effects proportional to the dose cannot be ob-
tained, and risks of adverse effects are increased.22
Thus, in controlling asthma, a more favorable out-
come can be achieved by adding controller(s) other
than inhaled corticosteroids rather than by simply in-
creasing inhaled corticosteroids.19 However, severe
acute exacerbations can be decreased by the increas-
ing amount of inhaled corticosteroid.19 Smoking re-
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Table　16　Recommended doses of inhaled corticosteroids by treatment steps
Agent Treatment steps 1-2 / Low dose Treatment step 3 / Medium dose Treatment step 4 / High dose
BDP-HFA 100-200 μg/day 200-400 μg/day 400-800 μg/day
FP-HFA 100-200 μg/day 200-400 μg/day 400-800 μg/day
CIC-HFA 100-200 μg/day 200-400 μg/day 400-800 μg/day
FP-DPI 100-200 μg/day 200-400 μg/day 400-800 μg/day
BUD-DPI 200-400 μg/day 400-800 μg/day 800-1,600 μg/day
BIS 0.5 mg/day 1.0 mg/day 2.0 mg/day
MF-DPI 100-200 μg/day 200-400 μg/day 400-800 μg/day
duces the effects of inhaled corticosteroids as well as
the respiratory function in patients with asthma.23
Aside from localized adverse effects, such as oro-
pharyngeal candidiasis and hoarseness, systemic ad-
verse effects of inhaled corticosteroids include effects
on the eyes (cataract and glaucoma), on the skin
(skin thinning and hemorrhagic), on the bone (osteo-
porosis), and inhibitory effects on the hypothalamic
pituitary adrenal function.24 After inhalation, gargling
is essential for alleviating the oropharyngeal symp-
toms and reducing systemic absorption as much as
possible.
It is difficult to make a conclusion regarding the ef-
fects on the adrenal cortex based on the previous
clinical studies. While conventional doses are gener-
ally acceptable, caution should be exercised for the
high dose and use in pregnant women is a concern.
However, BUD-DPI, administered during early preg-
nancy, is reported to have caused congenital malfor-
mation no more than usual and to have had no effects
on the course of pregnancy.25 The US FDA has certi-
fied the safety of BUD-DPI in pregnant women as
Category B. There is no evidence of the increased
risk of respiratory tract infection, including tuberculo-
sis, caused by inhaled corticosteroids in patients with
asthma, and inhaled corticosteroids are not contrain-
dicated for patients with active tuberculosis.
b) Long-acting β2 agonists (LABA): β2 agonists,
used as controllers are administered via inhalation,
patch, and oral route. β2 agonists, as controllers
should be used concomitantly with inhaled corti-
costeroids. When a LABA is combined with an in-
haled corticosteroid, the steroid increases the num-
ber of β2 receptors, and the β2 agonist promotes the
nuclear translocation of steroid receptors, thereby en-
hancing the steroid action. Furthermore, the com-
bined therapy of an inhaled corticosteroid and a
LABA can reduce the amount of the inhaled corti-
costeroid26 and increase the number of well-
controlled asthma patients. The combination of an in-
haled corticosteroid and a LABA is more effective
than an inhaled corticosteroid with a theophylline
sustained-release preparation.27 However, the inhala-
tion effects of a mixed solution of BIS and a β2 agonist
have not been demonstrated.
Salmeterol xinafoate is an inhaled LABA, which is
inappropriate for treatment when used alone,28 but
has high synergistic effects when combined with an
inhaled corticosteroid.29 Conventional long-acting
oral agents include procaterol hydrochloride, clen-
buterol hydrochloride, and mabuterol hydrochloride.
The tulobuterol patch, which was developed in Japan,
is also a long-acting agent that is useful in patients,
for whom inhalation and oral administration are diffi-
cult. It has a bronchodilator action, which continues
for 24 h. Its clinical usefulness when used concomi-
tantly with an inhaled corticosteroid has been re-
ported.30 LABA are highly safe in any formulation.
However, adverse effects include tremor, palpitation,
and tachycardia, and develop more frequently for the
oral agent, the patch, and inhaled agent in this order.
When adverse effects are seen, the dosage should be
reduced or administration should be discontinued ac-
cording to the complaint. Serious adverse effects in-
clude a decreased serum potassium level. LABA
should be used more carefully in patients with
ischemic heart disease, hyperthyroidism, and diabe-
tes mellitus. In addition, the adverse effects of the tu-
lobuterol patch include itching andor rash at the
patch area of the skin.
c) Compounding agent of inhaled corticosteroids
inhaled LABA (Table 17): In Japan, fluticasonesal-
meterol and budesonideformoterol are currently
used as compounding agents of an inhaled corti-
costeroid and a LABA, which are more effective than
when inhaled separately.31 Compounding agents
have the following advantages: (i) number of times
for inhalation can be decreased; (ii) excellent compli-
ance can be achieved; and (iii) use of LABA alone can
be avoided. Asthma treatment must be based on the
control level when using these compounding agents.
If the concomitant use of LABA can be omitted when
asthma is well controlled, a switch to an inhaled corti-
costeroid alone can be made.
d) Leukotriene receptor antagonists: Leukotrienes
(LT) C4, D4, and E4, are called cysteinyl LT (CysLTs),
whose receptors are CysLT1, CysLT2, and CysLT3. A
currently available leukotriene receptor antagonist
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Table　17　Daily doses of combination inhaler of corticosteroids and long-acting β2 agonists
Low dose Medium dose High dose
FP/SM (DPI)
100 μg/dose, 1 dose b.i.d. 250 μg/dose, 1 dose b.i.d. 500 μg/dose, 1 dose b.i.d.
200 μg/100 μg 500 μg/100 μg 1000 μg/100 μg
BUD/FM† (DPI)
One dose b.i.d. Two doses b.i.d. Four doses b.i.d.
320 μg/9 μg 640 μg/18 μg 1280 μg/36 μg
FP/SM (pMDI)
50 μg/dose, 2 doses b.i.d. 125 μg/dose, 2 doses b.i.d. 250 μg/dose, 2 doses b.i.d.
200 μg/100 μg 500 μg/100 μg 1000 μg/100 μg
FP, fl uticasone; SM, salmeterol; BUD, budesonide; FM, formoterol.
†Indicated in a delivered dose.
(LTRA) is a CysLT1 receptor antagonist. Three types
are available; pranlukast hydrate, zafirlukast, and
montelukast. LTRAs have a bronchodilator action and
inhibit airway inflammation, resulting in significant
improvement of asthma symptoms, respiratory func-
tion, inhalation frequency of as-needed inhaled β2 ag-
onist, airway inflammation, airway hyperresponsive-
ness, dosage of inhaled corticosteroids, asthma exac-
erbations, and patients’ QOL.32-34 LTRAs are particu-
larly useful as agents used concomitantly with an in-
haled corticosteroid in patients with asthma, which
cannot be completely controlled even with a medium
dose of an inhaled corticosteroid, because the addi-
tional administration of LTRAs is as effective as a dou-
ble dose of an inhaled corticosteroid.35 When com-
pared with LABA, LTRAs, as concomitant agents with
an inhaled corticosteroid, are less effective in improv-
ing symptoms and respiratory function and are al-
most equivalent in preventing exacerbation.36 LTRAs
are particularly useful for long-term management of
patients with asthma complicated by allergic rhinitis,
exercise induced asthma, and aspirin induced
asthma.
In some patients, respiratory function improves
early after the oral administration of a LTRA (at sev-
eral hours at the earliest, on the following day at the
latest), however, antiinflammatory effects develop
later. Thus, efficacy is generally judged in 2-4 weeks
after administration. While more reports have been
published on Churg-Strauss syndrome in patients
who received an LTRA than those who received other
anti-asthmatic drugs, no conclusion has been reached
on whether an LTRA is directly involved in the onset
of Churg-Strauss syndrome.37 LTRAs are generally
safe drugs, but caution should be exercised for zafir-
lukast considering severe hepatopathy and interac-
tion with other agents, such as warfarin, since it is
metabolized by CYP2C9. LTRAs seem to be relatively
safe for pregnant women.
e) Sustained-release theophylline: Theophylline
sustained-release preparation is a long-acting bron-
chodilator with antiinflammatory effects, such as inhi-
bition of infiltration of lymphocytes and eosinophils
into the airway,38 T cell proliferative response, cy-
tokine production, apoptosis induction of eosino-
phils,39 and recovery of steroid sensitivity through
histone deacetylase (HDAC) reactivation.40 While the
theophylline sustained-release preparation is clini-
cally less effective than inhaled corticosteroids, when
used concomitantly with low to medium doses of an
inhaled corticosteroid, the same effects as those ob-
tained with an increased amount of an inhaled corti-
costeroid can be achieved.41 However as a concomi-
tant drug with inhaled corticosteroids, sustained-
release theophylline at 300-400 mgday improved air-
way obstruction less than LABA27 and as good as or
less than LTRAs.42 The effective safety range of theo-
phylline is rather narrow, and the serum theophylline
level varies with various factors (age, smoking, drug
interaction, etc.), thus serum level monitoring may be
useful in avoiding adverse effects. Antiinflammatory
effects are obtained at 5-10 μgmL of serum theophyl-
line concentration, and importantly, a bronchodilator
action is achieved in a concentration-dependent man-
ner. No serious adverse effects are noted at serum
concentrations up to 20 μgmL. Monitoring the peak
serum level of the sustained-release preparation is dif-
ficult, thus the target serum level is 5-15 μgmL. The
adverse effects of theophylline, which are gastrointes-
tinal symptoms such as nausea and vomiting at initial
oral administration, can be prevented to some extent
by gradually increasing from the low dose (200 mg)
to the dose controlling asthma in each patient. Toxic
symptoms caused by increased serum levels include
nausea and vomiting, and can progress to tachycardia
and arrhythmia, and in the most severe cases, death
from convulsions. In pregnant women, no effect has
been noted on the frequency of fetal disorders while
appropriate serum levels are maintained.
f) Anti-IgE antibody: Omalizumab is a humanized
anti-human IgE monoclonal antibody that binds to
IgE to inhibit binding between IgE and the high affin-
ity IgE receptor, thereby decreasing the expression
of the high affinity IgE receptor on tissue mast cells
and circulating blood basophils. Antiinflammatory ef-
fects, such as a reduced number of eosinophils, T
cells, B cells, and Th2 cytokine-positive cells in the
sputum and airway tissue and decreased serum IL-5
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and IL-13 levels, have been reported.43,44
The dose and frequency of administration are de-
termined based on the dosage conversion table ac-
cording to patient weight and serum IgE level (30-700
IUmL serum IgE) to reduce the serum free IgE lev-
els to10 IUmL. Omalizumab has the following ef-
fects in patients poorly controlled even with a high-
dose inhaled corticosteroid: (i) preventing exacerba-
tion, (ii) reducing symptom score, (iii) improving
QOL, and (iv) reducing steroid dose.45 Omalizumab
should be used as a therapeutic agent in treatment
step 4 for severe persistent asthma, sensitized to per-
ennial inhalation antigens (mites, animals, fungi,
etc.). Omalizumab is effective in about 60% of pa-
tients. At 16 weeks after the initiation of administra-
tion, therapeutic effects are comprehensively judged
based on exacerbation frequency, QOL, respiratory
function, etc., to determine whether the administra-
tion should be continued.46 In a clinical study in Ja-
pan, the PEF rate, FEV1, and exacerbation frequency
were significantly improved in patients poorly con-
trolled with the concomitant use of a high-dose in-
haled corticosteroid and one or more controller
agents. It is unknown whether patients can be with-
drawn after long-term administration.
The major adverse effects are pain and swelling at
the injection site. An anaphylactic reaction, reported
as a serious adverse effect in 0.1-0.2% of patients over-
seas, could develop within 2 h after administration
(about 70% of the episodes), but some reactions are
reported to occur after 24 h. Symptoms may develop
both at initial administration and after multiple ad-
ministrations. Caution should be exercised for the de-
velopment of Churg-Strauss syndrome due to the re-
duced amount of systemic steroids. No teratogenicity
has been reported.
g) Antiallergics other than leukotriene receptor an-
tagonists: The following antiallergics are effective in
30-40% of patients with mild to moderate atopic
asthma, although 4-6 weeks or longer administration
period is needed to determine their efficacy. Safety of
oral antiallergics in fetuses during pregnancy has not
been demonstrated.
Mediator release suppressants: The main effect of
mediator antireleasers is the inhibition of the release
of chemical mediators from mast cells. Long-term use
of disodium cromoglycate (DSCG) inhibits airway in-
flammation in patients with atopic asthma.47
Histamine H1 antagonists: The main effect of these
agents is to antagonize action of histamine through
H1 receptors and beneficial for asthma accompanied
by allergic rhinitis or atopic dermatitis. Caution will
be exercised for adverse effects, such as sleepiness
and malaise.
Thromboxane A2 inhibitorsantagonists: Thromb-
oxane A2 synthesis inhibitors and thromboxane A2 re-
ceptor antagonists inhibit airway inflammation, im-
prove airway hyperresponsiveness, and improve im-
paired mucociliary transport. Their adverse effects in-
clude increased bleeding tendency, thus we should
be cautious about the concomitant use of other
agents with platelet aggregation inhibiting activity.
Th2 cytokine inhibitor: The major effects of
suplatast tosilate are inhibition of IL-4 and IL-5 pro-
duction from Th2 cells, inhibition of eosinophil infil-
tration in the airway mucosa, and alleviation of airway
hyperresponsiveness in patients with asthma.48 They
are effective in reducing the amount of an inhaled
corticosteroid.49
(2) Reliever agents
a) Short-acting inhaled β2 agonists: Short-acting in-
haled β2 agonists are regarded as reliever agents. In-
halation therapy using a pMDI, DPI, and nebulizer
shows an equivalent or higher bronchodilator action
compared with oral administration. However, there
are a few adverse effects, such as stimulation of the
cardiovascular system, skeletal muscle tremor, and
hypokalemia, which can be reduced by use of a
spacer. The increased number of times of the use can
be regarded as exacerbation and inhalation can be re-
peated as needed. If the effects are insufficient after
repeated inhalation every 20 min for 1 h, a physician
should be consulted. The agents are effective for the
prevention of allergen- or exercise-induced asthma
(EIA) and treatment of exacerbations.
b) Oral corticosteroids: For acute asthma attacks
(moderate exacerbations), an oral corticosteroid to-
gether with a short-acting β2 agonist, needs to be ad-
ministered for a short period (about 1 week). Treat-
ing asthma symptoms earlier by short-term admini-
stration (usually less than 1 week) of a medium- or a
high-dose oral corticosteroid (approximately 0.5 mg
kg prednisolone) prevents acute exacerbations, de-
creases emergency visits and hospitalization, and re-
duces the restrictions on daily life due to asthma at-
tacks. In short-term administration (less than 2
weeks), adrenocortical insufficiency (steroid with-
drawal syndrome) will not occur by rapid dose reduc-
tion or discontinuation.
c) Theophylline: Single use of oral aminophylline is
used as a reliever agent, whose dosage is based on
serum levels.
d) Inhaled anticholinergics: Inhaled anticholiner-
gics have additive effects with β2 agonists on acute
exacerbations.
(3) Other agents and therapies
a) Chinese herbal medicines: Administration of
Chinese herbal medicines is considered based on the
symptoms. Selection of an agent is based on the pa-
tient’s physical constitution, strength, and response
to disease at the time of administration; the empirical
process helps distinguishing responders and non-
responders before administration.
b) Other agents: Expectorants, such as carbociste-
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ine and fudosteine, may be effective in facilitating ex-
pectoration and macrolides may inhibit neutrophilic
inflammation observed in some patients with asthma.
However, accumulated evidence is not sufficient for
recommendation of either of these agents.
c) Specific immunotherapy: Allergen specific im-
munotherapy is indicated for patients with symptoms
caused by the inevitable relevant allergens and un-
controllable by appropriate therapy. This therapy in-
hibits cytokine production from Th2 cells and chemi-
cal mediator production from mast cells to improve
eosinophilic airway inflammation and airway hyperre-
sponsiveness.50
d) Nonspecific therapy: If no sufficient effect can
be achieved by general treatment, consider additional
use.
4.1.2. Stepwise Administration Plan
(1) Aim of asthma treatment
The aim of asthma treatment is to achieve normal res-
piratory function in the absence of symptoms or ad-
verse effects. In patients with airway remodeling, res-
piratory function cannot be improved to normal lev-
els; thus, it can be assessed based on their best val-
ues. The control status is determined based on Table
18, with the aim of asthma control.
(2) Principle for treatment
A better relationship between patients and physicians
largely depends on the effects of initial treatment,
which focus on improvement and stability of asthma
symptoms. Aside from using therapeutic agents for
asthma, it is important to avoid and eliminate sensitiz-
ing allergens (mites, fungi, cockroaches, animals, pol-
len, etc.) and exacerbating factors, such as passive
and active smoking and overfatigue. Allergen immu-
notherapy (hyposensitization) is considered espe-
cially for young patients with asthma complicated by
allergic rhinitis. The Expert Panel Report 3 (EPR3)14
states that immunotherapy should be considered for
patients with mild to moderate asthma caused by en-
vironmental allergens. Management of concomitant
diseases, such as allergic rhinitis, is also important.
Asthma treatment is divided into 4 treatment steps
that are outlined in the following section, based on its
intensity. The aim of drug therapy is to achieve the
maximum effect using the minimum dose. Symptoms
at the initiation of therapy, those at consultation, and
therapeutic situation are comprehensively evaluated
to determine the appropriate treatment step. Treat-
ment is stepped up when asthma symptoms deterio-
rate or sufficient control cannot be achieved with the
pharmacotherapy being provided. Maintenance ther-
apy is determined by referring to asthma symptoms
and PEF rates. We should be cautious about step-
down to prevent asthma symptoms from deteriora-
tion, and the patient should be informed of treatment
against exacerbation during dose reduction.
(3) Four treatment steps of asthma (Table 5)
a) Treatment step 1: One controller agent plus re-
liever agent: A short-acting inhaled β2 agonist without
controllers may be administered only to patients with
rare asthma symptoms (less than once a month),
where no long-term management agent is needed. It
should be emphasized that many patients with
asthma underreport their symptoms. For patients
who develop symptoms once or more a month, an in-
haled corticosteroid (low dose) is recommended as a
controller agent.20 If inhaled corticosteroids cannot
be used, or adverse effects develop after inhalation,
LTRAs32 or sustained-release theophylline38 can be
substituted, but their antiinflammatory activities are
inferior to those of inhaled corticosteroids. Short-
acting inhaled β2 agonists are administered on an as-
needed basis for exacerbations.
b) Treatment step 2: Two controller agents plus re-
liever agent: In addition to inhaled corticosteroids
(low to medium dose), a LABA,28,29 or an LTRA36,51
or sustained-release theophylline41 can be used. A
compounding agent of LABA and inhaled corticoster-
oid can also be used.52 Consider LTRAs mainly for pa-
tients with coexisting allergic rhinitis, aspirin induced
asthma, and sympathetic nerve stimulation caused by
a LABA or theophylline. Depending on disease condi-
tions, antiallergics other than LTRAs can be used
concomitantly.
c) Treatment step 3: Three or more controller
agents plus reliever agent: In addition to a continu-
ously administered inhaled corticosteroid (medium
to high dose), a LABA and an LTRA, or LABA with a
sustained-release theophylline or both are used con-
comitantly.
d) Treatment step 4: Controller agents plus reliever
agent plus additional therapy: In addition to continu-
ous administration of an inhaled corticosteroid (high
dose), concomitantly use a LABA, LTRA, or
sustained-release theophylline. Anti-IgE antibody
(omalizumab) is effective in poorly controlled pa-
tients sensitized to perennial allergens, whose serum
total IgE value is within a therapeutic target range
(30-700 IUmL).45 The dose of an anti-IgE antibody is
determined based on the total IgE value and body
weight, using a dosage conversion table. Its effects
are evaluated 16 weeks after administration, and if ef-
fective, administration is continued. Oral corticoster-
oids should be intermittently administered for a short
period to avoid prolonged administration wherever
possible. Specifically, about 0.5 mgkg or the equiva-
lent amount of prednisolone are administered for a
short period (usually less than 1 week); then a high-
dose inhaled corticosteroid is subsequently used. To
insufficiently controlled patients, who need prolonged
administration of an oral corticosteroid, a shorter-
acting oral corticosteroid (prednisolone) can be ad-
ministered in the morning once daily or every other
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Table　18　Assessment of control status
Well-controlled
 (meet all the criteria)
Insufficiently-controlled
(meet 1 or 2 criteria) Poorly-controlled
Asthma symptoms (in the 
daytime or at night) None Once or more a week
Meet 3 or more criteria of 
insufficient control
Use of reliever None Once or more a week
Limitation of activities, includ-
ing exercise None Restricted
Lung function
(FEV1 and PEF)
Within a normal range Predicted value or <80% of the best value
Diurnal (weekly) variation in 
PEF <20% ≥20%
Exacerbation None Once or more a year Once or more a month†
†Determine patients with one or more exacerbations a month as being poorly controlled, even if they do not meet the other criteria.
Table　19　Treatment steps for symptoms of untreated patients
Treatment step 1 Treatment step 2 Treatment step 3 Treatment step 4
Symptoms
(Mild intermittent symp-
toms) 
- Less than once a 
week
- Mild intermittent
- Occur at night less 
than twice a month
(Mild persistent symp-
toms) 
- Once or more a 
week, not every day
- Disturb everyday life 
and sleep once or 
more a month
- Occur at night twice 
or more a month
(Moderate persistent) 
- Every day
- Require short-acting 
inhaled β2 agonist al-
most every day
- Disturb everyday life 
and sleep once or 
more a week
- Occur at night once 
or more a week
(Severe persistent)
- Frequently exacerbated 
even under treatment
- Every day
- Restrict everyday life
- Frequently occur at 
night
day to maintain the minimum dose (5 mg). Caution
should be emphasized for adrenal insufficiency in
switching from long-term administration of an oral
corticosteroid to a high-dose inhaled corticosteroid.
(4) Actual treatment
a) Selection of treatment steps: In untreated pa-
tients, treatment steps are selected based on the
symptoms shown in Table 19. Specifically, treatment
steps are selected as follows: (i) treatment step 1 for
mild intermittent symptoms, (ii) treatment step 2 for
mild persistent symptoms, (iii) treatment step 3 for
moderate persistent symptoms, and (iv) treatment
step 4 for severe persistent symptoms. In patients un-
der drug therapy, continue the present treatment if
the asthma is controlled, or consider step-down if
asthma control continues for 3-6 months, based on
the assessment of the control status in Table 18. One
step-up is required for insufficient control, and 2 step-
ups for uncontrolled asthma.
b) Monitoring and treatment during follow-up:
“Monitoring items relevant to the assessment of con-
trol status” are summarized in Table 20.
c) Management for difficult-to-treat patients: Early
referral is recommended for patients with underlying
diseases, such as aspirin induced asthma, Churg-
Strauss syndrome, other systemic vasculitis, and al-
lergic bronchopulmonary aspergillosis, because, in
addition to the above treatment steps, the continuous
administration of a systemic steroid or immunosup-
pressant may be needed. Uncontrolled or partly con-
trolled patients need adequate instruction regarding
daily medication, inhalation methods, and manage-
ment against acute exacerbation and are provided
with an asthma diary that records the dosages and
timing of inhalation and medication. Patients with
worsening symptoms are instructed to follow an
emergency manual immediately. In addition, dose re-
duction strategies are instructed. Furthermore, pa-
tients should have contact information with them-
selves useful when acute exacerbation occurs, ad-
dresses of emergency hospitals, and an “asthma noti-
fication card,” which enables physicians, other than
attending physicians, to conduct emergency treat-
ment immediately.
(5) Guidelines for self-management
An asthma management-zone system enables a pa-
tient to self-monitor their asthma status and find
signs of exacerbations to start immediate manage-
ment. The zones imitate the colors of traffic lights;
the green zone indicates safety, the yellow zone cau-
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Table  20　Items useful for control assessment
 1. Peak expiratory fl ow (PEF) and subjective symptoms recorded by asthma diary (or interview sheet)
 2. Spirometry
 3. Arterial blood gas assay and pulse oximeter
 4. Airway hyperresponsiveness
 5. Sputum and peripheral blood eosinophils
 6. Chest radiograph and electrocardiogram
 7. Specifi c IgE antibody and total IgE
 8. Serum theophylline level
 9. Plasma cortisol level
10. Fraction of exhaled nitric oxide (FeNO)
11. Routine biochemical examination, blood count, and urinalysis
Items 1 and 2 are useful for daily control assessment. Item 10 is under investigation. Items 2, 4, 5, 7, and 10 are useful for asthma diag-
nosis. Items 3, 6, and 11 are useful for exacerbated asthma. Items 8, 9, and 11 are recommended for monitoring of pharmacotherapy.
tion, and the red zone warning. According to the clas-
sification of symptom severity in asthma, the yellow
zone corresponds to wheezingchest tightness (mild)
or moderate symptoms, and the red zone corre-
sponds to slightly severe moderate to severe symp-
toms. Predicted PEF rates or % for the best value (%
PEF) is indicated in the zones. Actual values enable
patients to understand the zones. However, since %
PEF is a rough index, physicians should create indi-
vidualized plans for patients.
a) Green zone: Controlled (Table 18). %PEF is
80%. Patients are in a safe condition and step-down
can be considered when a patient is in the green zone
for 3 months or longer.
b) Yellow zone: Insufficiently controlled. %PEF is
defined as 50-80%. Caution should be exercised and
step-up of treatment is required under such condi-
tions.
c) Red zone: Uncontrolled. %PEF rate is defined as
<50% of the patient’s best value. A short-acting β2 ago-
nist should be inhaled immediately and a physician
should be consulted if no improvement is noted.
4.2. MANAGEMENT OF ACUTE EXACERBATION
IN ADULTS
4.2.1. Therapeutic Agents
(1) Inhaledβ2 agonists
Higher therapeutic effects can be obtained by re-
peated administration of a small dose (1-2 puffs a time
using a portable pMDI) for a fixed period than by sin-
gle administration of a high dose.53 Correct inhalation
procedures are critical; for acute asthma symptoms, a
short-acting β2 agonist is inhaled every 20 min for the
first hour and subsequently every hour until improve-
ment is noted. Inhalation using a spacer is more effec-
tive54 because it causes less adverse effects, however,
if adverse effects, such as marked tremor and palpita-
tion develop, the inhalation should be discontinued. A
nebulizer is effective in allowing continued inhalation
coupled with oxygen. Adding an inhaled anticholiner-
gic may provide an additive bronchodilator action.55
(2) Subcutaneous injection of 0.1% adrenaline
Catecholamine formulation (adrenaline: BosminⓇ,
etc.) can be administered when no sufficient effects
can be obtained with an inhaled β2 agonist, but cau-
tion should be exercised for arrhythmia, cardiac ar-
rest, etc. Subcutaneous injection of 0.1% adrenaline
(0.1-0.3 mL) provides a bronchodilator action through
the relaxation of the bronchial smooth muscles (β ef-
fect) and the removal of airway mucosal edema (α ef-
fect). The administration can be repeated every 20-30
min, while monitoring the pulse, which should be
kept 130min. This agent is contraindicated for pa-
tients with complications, such as arteriosclerosis, hy-
perthyroidism, diabetes mellitus, severe arrhythmia,
psychoneurosis, and glaucoma [except for open-angle
(simple) glaucoma]. In addition, caution should be
exercised for the following agents because of contra-
indication of concomitant use. i) Inhaled halogen-
containing anesthetics, such as halothane carry in-
creased risks of tachycardia and ventricular fibrilla-
tion. ii) Antipsychotics (butyrophenones, phenothi-
azines, iminobenzyls, zotepine, and risperidone) and
α blockers have vasopressor actions, which are re-
versed in this combination, and may result in hy-
potension. iii) Catecholamine formulation, such as
isoproterenol, and adrenergic agents is contraindi-
cated for cases other than emergencies, such as re-
suscitation, because arrhythmia and, in some cases,
cardiac arrest may develop when used concomitantly.
iv) A tulobuterol patch can be concomitantly used
with precaution, but is contraindicated for concomi-
tant use with fenoterol.
(3) Theophylline
The effective serum concentration of theophylline is
8-20 μgmL (<15 μgmL in children), but adverse ef-
fects will occur when exceeding this range. Intrave-
nous infusion of aminophylline (6 mgkg) has a bron-
chodilator action, has positive effects on the respira-
tory drive and respiratory muscles; thus, is effective
Adult Asthma
Allergology International Vol 60, No2, 2011 www.jsaweb.jp 133
Table　21　Factors infl uencing serum theophylline level
Decreased clearance (increases serum level)
- Aging (50 years or older) and extreme obesity
- Complications, such as hepatopathy, heart failure, virus infection, and fever
- Agents: allopurinol, macrolides (erythromycin, clarithromycin, and roxithromycin), cimetidine, diazepam, new quinolones 
(ENX, CPFX, and TFLX), thiabendazole, propranolol (contraindicated for asthma), etc.
Increased clearance (decreases serum level)
- Smoker (who smoke ≥15 cigarettes/day)
- Agents: barbituric acid, antiepileptics (carbamazepine and phenytoin), rifampicin, isoproterenol, etc.
Table　22　High-risk group of asthma exacerbation
High-risk group meet any one of the following criteria:
1. Receiving systemic steroid administration, or immediately after the administration was discontinued.
2. History of hospitalization due to asthma attack in the past 1 year
3. Emergency visit due to asthma attack in the past 1 year
4. Tracheal intubation due to asthma attack in the past
5. Coexisting mental disorder
6. Noncompliance with asthma treatment plan
7. Not using an inhaled corticosteroid
8. Excessive use of short-acting β2 agonist
in treating acute asthma attacks.56 Aminophylline has
additive effects for β2 agonists56 and its use decreases
hospitalization rates due to asthma attacks. The level
of serum theophylline should be monitored for dose
adjustment when the expected effects are not ob-
tained, or when higher serum levels are suspected.
Initial administration is conducted with aminophylline
(6 mgkg, 250 mgampule) in 200-250 mL of isotonic
fluid, assuming that theophylline was insufficiently
administered before exacerbation and that theophyl-
line clearance was normal. For safety reasons, the
first half is infused over 15 min and the remaining
half over 45 min. If600 mg of sustained-release the-
ophylline is administered daily, serum theophylline
level is 8 μgmL, or reduced clearance is sus-
pected, the dose of aminophylline should be reduced
to half or less. If toxic symptoms of theophylline
(headache, nausea, vomiting, tachycardia, arrhyth-
mia, etc.) occur during administration, the intrave-
nous infusion must be discontinued immediately.
Even if subjective symptoms are improved after intra-
venous infusion, patients should rest for about 30
min. Monitor serum levels of theophylline during
treatment wherever possible. We should be cautious
about intoxication, particularly when there are factors
affecting theophylline clearance, as shown in Table
21. For continuous administration of aminophylline, 1
ampule (250 mg) of aminophylline is added to 500
mL of maintenance infusion to be used in continuous
intravenous infusion for 5-7 h (about 0.6-0.8 mgkg
h) according to the individual’s physical constitution.
The speed of intravenous infusion should be adjusted
to achieve 8-20 μgmL of serum theophylline levels.
The PaO2 may transiently fall during continuous ad-
ministration of aminophylline, thus in the event that
hypoxemia develops, use oxygen inhalation (1-2 L
min with nasal cannulas). An intravenous infusion kit
for children, which allows easy adjustment of infusion
speed, is recommended for intravenous infusion.
(4) Corticosteroids
Corticosteroids (steroids) are recommended for pa-
tients with exacerbated symptoms, whose bronchodi-
lator action is not enough, those with moderate or se-
vere exacerbations, and those who are already receiv-
ing a steroid.57 The initial dose is set at 200-500 mg of
hydrocortisone or 40-125 mg of methylpredniso-
lone,57 with subsequent intravenous infusion of 100-
200 mg of hydrocortisone or 40-80 mg of methylpred-
nisolone every 4-6 h as needed. However, consider-
ing the time and safety until clinical effects of steroid
develop (approximately 4 h), intravenous infusion for
about 30-60 min is recommended as initial admini-
stration. In patients with aspirin induced asthma, ster-
oid phosphate esters should be used, because steroid
succinate esters may induce worsening in 40-60% of
patients.58
Systemic steroid administration is indicated for pa-
tients with moderate or severe exacerbations, history
of severe asthma attack requiring systemic steroid
administration, history of advanced severe asthma at-
tack requiring hospitalization, and high risks of exac-
erbations (Table 22).
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Table　23　Management strategy based on the intensity of asthma attack (acute exacerbation)
Exacerbation intensity‡ Dyspnea Movement
Laboratory data†
PEF SpO2 PaO2 PaCO2
Wheezing/
chest tightness
Dyspnea when in a hurry
Dyspnea when in moving
Almost normal
≥80% ≥96% Normal <45 mmHg
Mild
(mild exacerbation)
Dyspnea but no trouble 
with lying down Slight dyspnea
Moderate
(moderate exacerbation)
Dyspnea with trouble 
with lying down
Difficulty in moving
Difficulty in walking
60-80% 91-95% >60 mmHg <45 mmHg
Severe
(severe exacerbation) Dyspnea, cannot move
Abasia
Difficulty in speaking
<60% ≤90% ≤60 mmHg ≥45 mmHg
Serious
Respiratory attenuation
Cyanosis
Respiratory arrest
Anepia
Akinesia
Confusion
Impaired consciousness
Incontinence
Immeasurable ≤90% ≤60 mmHg ≥45 mmHg
Aim of treatment: Elimination of dyspnea, normal movement, normal sleep, and normal everyday life. PEF rate is ≥80% of a predicted 
value or the best value. Oxygen saturation >95% (values after bronchodilator administration). No exacerbation of asthma symptoms by rou-
tine medication and inhalation.
†Refer to values after bronchodilator administration.
‡Determine exacerbation grade based on the severity of dyspnea, referring to other items. If symptoms of different exacerbation intensi-
ties coexist, use more severe one.
§ICU or hospital rooms where tracheal intubation, assisted ventilation, bronchial lavage, etc., can be used and continuous monitoring can 
be conducted using a sphygmomanometer, electrocardiogram, and pulse oximeter. Since intubation and mechanical ventilation during se-
vere respiratory insufficiency are often hazardous to life, their use should be conducted by experienced specialists when inevitable in emer-
gency.
¶Repeat 1-2 puffs of β2 agonist pMDI twice at an interval of 20 min. If ineffective or exacerbated, use 1 tablet of β2 agonist or 200 mg 
choline theophylline or aminophylline.
‖ Inhalation of β2 agonist using a nebulizer: Repeat every 20-30 min. Monitor the pulse to be kept ≤130/min. 
#Bosmin® (0.1% adrenaline): Bosmin® (0.1-0.3 mL) can be repeatedly administered at intervals of 20-30 min. Keep the pulse ≤130/min. 
This agent is contraindicated for patients with ischemic heart disease, glaucoma [except for open-angle (simple) glaucoma], and 
hyperthyroidism. Sphygmomanometry and electrocardiogram monitor are required for patients with hypertension.
(5) Anticholinergics
An anticholinergic, added to a β2 agonist during acute
exacerbations, may enhance the bronchodilator ac-
tion to improve symptoms and respiratory function59
and reduce hospitalization rate.
(6) Oxygen inhalation
Oxygenation can be initiated in patients with severe
dyspnea or <80 mmHg PaO2 (<95% SpO2) with a tar-
get value of 80 mmHg PaO2 or about 95% SpO2. Si-
multaneously, prepare for endotracheal intubation
and ventilator.
(7) Other therapies
•Antibiotics: Antibiotics are administered to pa-
tients with bacterial infection accompanied by fe-
ver and purulent sputum.
•Expectorants and mucolytic agents on sputum:
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Treatment
Home remedy, emergency visit and hospitalization, and ICU 
treatment§
Inhaled β2 agonist, as-needed¶
Theophylline agent, as-needed
Home remedy
Inhaled β2 agonist, as-needed¶
Theophylline agent, as-needed
Home remedy
Repeated inhalation of β2 agonist using a nebulizer‖ Emergency visit
Subcutaneous injection of Bosmin® (0.1% adrenaline)# - If symptoms improve within 1 h, allow the patient to go home.
Intravenous infusion of aminophylline†† - Insufficient response within 2-4 h
Intravenous infusion of steroid‡‡ - No response within 1-2 h
Oxygen§§ Hospital treatment → Switch to treatment for severe asthma
Consider anticholinergic inhalation.
Subcutaneous injection of Bosmin® (0.1% adrenaline) #
Continuous infusion of aminophylline ¶¶
Repeated intravenous infusion of steroid ‡‡
Oxygen ‖‖
Repeated inhalation of β2 agonist using a nebulizer‖
Emergency visit
If no response within 1 h, hospitalization.
If exacerbated, switch to treatment for serious exacerbation.
Continue the above treatment.
If symptoms and respiratory function are exacerbated, con-
duct intubation§.
In spite of oxygen inhalation, ≤50mmHg PaO2 and/or 
rapidly elevated PaCO2 with impaired consciousness.
Mechanical ventilation§
Bronchial lavage
Consider general anesthesia (using isofl urane, sevofl urane, 
enfl urane, etc.).
Immediate hospitalization and ICU treatment§
††Intravenous infusion of aminophylline (6 mg/kg) in 200-250 mL of isotonic fl uid: Administer the fi rst half for about 15 min and the re-
maining half for about 45 min. If toxic symptoms (headache, nausea, palpitation, extrasystole, etc.) occur, discontinue the infusion. When a
sufficient amount of theophylline was administered before exacerbation, reduce the dose of aminophylline to half or less. Routinely, mea-
sure serum theophylline levels in patients receiving it, wherever possible.
‡‡Intravenous infusion of steroids: Intravenous infusion of 200-500 mg of hydrocortisone, 40-125 mg of methylprednisolone, or 4-8 mg of 
dexamethasone or betamethasone. Subsequently, conduct intravenous infusion of 100-200 mg of hydrocortisone, or 40-80 mg of methyl-
prednisolone every 4-6 h as needed, or 4-8 mg of dexamethasone or betamethasone every 6 h as needed, or oral prednisolone (0.5 mg/kg/
day).
§§Oxygen inhalation (1-2 L/min with nasal cannula).
¶¶Continuous intravenous infusion of aminophylline: Following the first intravenous infusion (see the above††), conduct continuous intra-
venous infusion of 250 mg of aminophylline (1 tube) for 5-7 h (about 0.6-0.8 mg/kg/h). Monitor serum theophylline levels to be maintained at 
10-20 μg/mL (15-20 μg/mL to achieve the maximum effects). If toxic symptoms occur, discontinue the infusion.
‖‖Oxygen inhalation: Target PaO2 is about 80 mmHg.
They are not essential.
•Analgesics: They are not generally used.
•Antihistamines: They have no immediate effects
on acute asthma symptoms.
•Fluid replacement: Caution should be exercised
for dehydration, although a large amount of fluid
replacement is generally unnecessary.
4.2.2. Management at Home
Since asthma symptoms vary widely in their severity,
management against acute exacerbation must be tai-
lored to their severity, and patients must be informed
about these approaches. A self-management plan (ac-
tion plan) should be provided to the patient to show
specific instructions for each condition.60 To treat
wheezingchest tightness and moderate asthma
symptoms, 1-2 puffs of a short-acting inhaled β2 ago-
nist (see a package insert) should be administered
using a pMDI. If the effects are insufficient, repeat in-
halation every 20 min for 1 h and subsequently once
an hour. At this time, an oral β2 agonist or theophyl-
line drug (choline theophylline or aminophylline) can
be used concomitantly. Patients can be treated at
home when these agents eliminate symptoms (80%
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of predicted PEF rate or the best value) and their ef-
fect continues for 3-4 h. However, if no therapeutic ef-
fect can be achieved, an oral corticosteroid (about 15-
30 mg of prednisolone) should be administered and
an emergency outpatient unit should be visited.
4.2.3. Treatment Procedures of Emergency Out-
patients (Table 23)
Immediately upon arrival, the severity of the asthma
attack should be determined. Asthma attack intensity
is classified as follows: (i) mild symptoms with dysp-
nea but no trouble with lying down, (ii) moderate
symptoms in lying down and walking difficulty, (iii)
severe symptoms causing motor difficulty, abasia,
and speech difficulty, and (iv) serious symptoms
causing cyanosis, impaired consciousness, and respi-
ratory arrest.
It is also important to observe the following points
for quick and efficient history examination based on
severity, however, caution should be exercised not to
delay treatment because of the oral consultation.
•Time of onset and cause of exacerbation.
•Extent of exercise limitation and sleep distur-
bance.
•History of recent drug administration, agent ad-
ministered last, time of the last administration,
and use of steroids.
•Hospitalization and emergency visit due to
asthma.
•History of respiratory insufficiency and intuba-
tion due to asthma.
•Cardiopulmonary diseases and complications.
•History of aspirin induced asthma and drug aller-
gies.
(1) Wheezingchest tightness, mild symptoms
(mild exacerbation)
a) Assessment: “Wheezing and chest tightness”
are symptoms, such as wheezing during breathing
and chest tightness, but movements are almost nor-
mal. “Mild symptoms” indicates mild dyspnea during
rest, which is so mild as to allow lying down, but
causes difficulty with movement. These symptoms
place no restrains on everyday life. Diagnosis is
based on a PEF rate, which is 80% of a predicted
value or the best value (after bronchodilator admini-
stration). New patients should be queried about his
her history of asthma and other diseases. All patients
should be questioned about treatments received after
onset and undergo a physical examination, such as
chest auscultation. Patients with dyspnea suspected
to be due to causes other than asthma, should be ex-
amined by radiography and electrocardiogram.
b) Treatment: Inhale a β2 agonist using pMDI, DPI,
or nebulizer: If symptoms disappear and conditions
are stable for 60 min without additional treatment, en-
sure that there is no airway obstruction (80%
%PEF) and allow the patient to go home. If symptoms
are not improved and airway obstruction continues
(80% %PEF), conduct moderate or higher level
treatment [i.e., (2) b) (ii) as below].
(2) Moderate symptoms and duration of mild
symptoms (moderate exacerbation)
a) Assessment: Moderate asthma symptoms (i.e.,
dyspnea and orthopnea during rest, precluding move-
ments). Diagnosis is based on the PEF rate, which is
60-80% of a predicted value or the best value. When
the patient is found to have suffered from asthma in
history taking, check habitual exacerbations and
treatment to be conducted for several days after the
onset. Examine the entire lungs for continuous rale
and check that there is no cyanosis. For differential
diagnosis of other diseases, conduct various examina-
tions, such as chest radiography, electrocardiogram,
blood count, arterial blood gas analysis (see Table 2).
b) Treatment:
(i) Administer an inhaled β2 agonist, 0.3-0.5 mL, di-
luted in an appropriate volume of physiological saline,
using a nebulizer and repeat the inhalation every 20-
30 min. The pulse should be maintained at 130
min. pMDI also provides equivalent effects. If symp-
toms improve within 20-60 min and are stable for 60
min after the last administration (%PEF is80%) and
SpO2 is >95%, allow the patient to go home. If symp-
toms do not improve (%PEF is 80%), the following
treatments should be conducted.
(ii) Intravenous infusion of aminophylline (6 mg
kg, 250 mgampule) in 200-250 mL of isotonic fluid.
For safety reasons, administer the first half for about
15 min and the remaining half for about 45 min. If a
sufficient amount of theophylline was administered
before exacerbation, reduce the dose of aminophyl-
line to half or less. If toxic symptoms of theophylline
(headache, nausea, vomiting, tachycardia, arrhyth-
mia, etc.) occur during infusion, immediately discon-
tinue the administration. Monitor serum theophylline
levels during treatment wherever possible.
(iii) Intravenous infusion of 200-500 mg of hydro-
cortisone, 40-125 mg of methylprednisolone, or 4-8
mg of dexamethasone or betamethasone: Systemic
steroid administration should be initiated immedi-
ately to patients with moderate or worse exacerba-
tions, who respond poorly to initial treatment with an
inhaled β2 agonist. Steroid administration should be
initiated immediately, as described above, to patients
who are receiving a high dose of an inhaled corti-
costeroid (FP 800 μgday) or are regularly receiv-
ing an oral corticosteroid, or who belong to a high-
risk group61 (Table 22). Steroid succinate esters
should be avoided in patients with aspirin induced
asthma. Furthermore, a 1-h intravenous infusion is
recommended for patients in whom the presence or
absence of aspirin induced asthma is unknown, or
who receive the agent for the first time.
(iv) Subcutaneous injection of 0.1-0.3 mL of 0.1%
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adrenaline: Adrenaline can be repeatedly adminis-
tered at intervals of 20-30 min as needed. The pulse
should be 130min and caution should be exer-
cised for dehydration and metabolic acidosis. In addi-
tion, caution should be exercised for agents, such as
halothane, antipsychotic, α blocker, and catechola-
mine, whose concomitant use is contraindicated. This
agent is contraindicated for patients with complica-
tions, such as arteriosclerosis, hyperthyroidism, glau-
coma [except for open-angle (simple) glaucoma], dia-
betes mellitus, serious arrhythmia, and psychoneuro-
sis. This agent is preferably avoided for pregnant
women. Hypoxemic patients are at high risk for ad-
verse effects.
(v) Oxygen inhalation: Nasally administer oxygen
at 1-2 Lmin to patients with severe dyspnea, 80
mmHg PaO2, or95% SpO2.
c) Action plan after treatment
(i) Favorable response: When wheezing and dysp-
nea are absent for 1 h (80% %PEF, >95% SpO2), al-
low the patient to go home and step up long-term
treatment. Subsequently, apply medications for long-
term management to an appropriate treatment step of
asthma (Table 5). In patients receiving an oral ster-
oid, consider adding or increasing the dose of corti-
costeroid for 1-2 weeks.
(ii) Insufficient response: Mild wheezing and con-
tinued dyspnea (<80% %PEF, 95% SpO2). Continue
the treatment but if symptoms are not improved
within 2-4 h, consider hospitalization.
(iii) No response: Marked extensive wheezing and
dyspnea (orthopnea) (70% %PEF) persist. Continue
the treatment, but if the symptoms are not improved
within 1-2 h after addition of an intravenous steroid,
consider hospitalization for treatment of serious
symptoms [(3) b) (ii)].
(3) Severe symptoms (severe exacerbation) or
continued moderate symptoms
a) Assessment: In patients with asthma symptoms
in emergency department, briefly record physical
findings to determine severity and differentiate them
from other diseases that cause dyspnea. Subse-
quently, ask short, appropriate questions about the
causes of exacerbation and previous treatment.
(i) Symptoms and physical findings: Patients with
serious symptoms take hunched position, and cannot
move because of dyspnea. They may suffer from
speech difficulty, confusion, or unconsciousness. Ac-
cessory respiratory muscles are used for breathing,
with the suprasternal space depressed. Usually,
marked wheezing is heard in the chest. Attenuation
or elimination of breath sounds indicates respiratory
arrest or its signs, but cyanosis is usually absent.
(ii) Tests: Generally, a respiratory function test
cannot be performed. If possible, PEF is <60% of a
predicted value or the best value. Blood gas analysis
is more reliable to determine severity. Severe airway
obstruction is indicated at 90% SpO2, 45 mmHg
PaCO2, and60 mmHg PaO2. Dyspnea due to other
causes is differentiated from asthma using blood
count, chest radiography, electrocardiogram, etc.
b) Treatment
(i) Initial treatment: In patients with serious symp-
toms, who cannot move and have speech difficulty,
establish venous access immediately, initiate treat-
ment with an inhaled β2 agonist using a nebulizer,
and administer adrenaline, aminophylline, and ster-
oids according to the treatment for moderate exacer-
bation.
•Administer 0.3-0.5 mL of an inhaled β2 agonist,
diluted in a physiological saline, using a nebu-
lizer.
•Intravenous infusion of aminophylline (6 mgkg,
250 mgampule) in 200-250 mL of isotonic fluid:
Administer the first half for about 15 min and the
remaining half for about 45 min. When a suffi-
cient amount of theophylline was administered
before exacerbations, reduce the dose of amino-
phylline to half or less.
•Intravenous infusion of 200-500 mg of hydrocorti-
sone or 40-125 mg of methylprednisolone, or 4-8
mg of dexamethasone or betamethasone: Avoid
steroid succinate esters in patients with aspirin
induced asthma. In addition, 1-h intravenous in-
fusion is recommended for patients, in whom the
presence or absence of aspirin induced asthma is
unknown, or who receive the agent for the first
time.
•Subcutaneous injection of 0.1-0.3 mL of 0.1%
adrenaline: Adrenaline can be repeatedly admin-
istered at intervals of 20-30 min as needed. Keep
pulse 130min. Caution should be exercised
for the presence of the above contraindications.
•Oxygen inhalation: Target PaO2 in oxygenation
is around 80 mmHg. Caution should be exer-
cised for CO2 narcosis in patients complicated by
COPD. In poorly responsive patients, check nor-
mal consciousness and introduce non-invasive
positive pressure ventilation (NPPV), intubation,
mechanical ventilation, etc. immediately depend-
ing on the patient’s status. NPPV improves the
patient’s breathing pattern through pressure
support ventilation (PSV) and avoidance of air-
way collapse by end-expiration by positive end
expiratory pressure (PEEP), and thus may be ef-
fective in terminating the vicious circle during
acute asthma attack.62 However, its efficacy
should be further investigated. Consider hospi-
talization of patients at this stage. Immediately
hospitalize patients if no improvement is noted
within 1 h after treatment.
(ii) Continuous treatment:
•Continuous intravenous infusion of aminophyl-
line at 0.6-0.8 mgkgh: Target serum level of
aminophylline is 8-20 μgmL. If symptoms de-
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Table　24　Conditions requiring tracheal intubation
- Severe ventilatory impairment or cardiac or respiratory 
arrest
- Marked respiratory muscle fatigue
- <50 mmHg PaO2 even after maximum oxygenation
- ≥5 mmHg/h elevation in PaCO2
- Marked elevation in PaCO2 and consciousness disorder
velop, for which intoxication is suspected, imme-
diately slow down or discontinue the administra-
tion to examine excessive dosage by measuring
the theophylline level. Consider various factors
influencing serum theophylline level (see Table
21).
•Intravenous infusion of 100-200 mg of hydrocorti-
sone or 40-80 mg of methylprednisolone every 4-
6 h as needed: Alternatively, intravenous infu-
sion of 4-8 mg of dexamethasone or betametha-
sone every 6 h as needed. Alternatively, addi-
tional intravenous infusion of prednisolone (0.5
mgkgday), 100-200 mg of oral hydrocortisone,
or 40-80 mg of methylprednisolone every 4-6 h as
needed, or 4-8 mg of dexamethasone or be-
tamethasone every 6 h as needed. Since hydro-
cortisone causes edema when administered for 3
days or longer, switch to a different steroid. Ad-
minister an oral prednisolone (0.5 mgkg, 20-30
mgday) once in the morning. After remission,
discontinue the administration within 7-14 days
or reduce it to the usual dose used before this
episode of attacks. Reportedly, there is no advan-
tage of tapering the dose of an oral corticosteroid
after remission. Instead, the administration can
be discontinued abruptly.63 Initiate the admini-
stration of an inhaled corticosteroid when inhala-
tion becomes possible during the course.
•Oxygen inhalation: Continuously administer an
optimal dose.
(4) Serious asthma symptoms and emergency
(serious exacerbation)
a) Assessment: Conduct emergency care (e.g., en-
dotracheal intubation and artificial respiratory man-
agement), when severe ventilatory impairment or res-
piratory arrest occurs, when there is no response to
the above treatments, when PaO2 is <50 mmHg even
after maximum oxygenation andor rapid increase of
PaCO2 with impaired consciousness occurs, or when
PaCO2 is rapidly increased to 5 mmHg an hour
based on arterial blood gas analysis. If PaCO2 ex-
ceeds 45 mmHg, prepare intubation for artificial res-
piratory management. Table 24 shows cases that re-
quire endotracheal intubation. Since intubation often
accompanies risks, ask an experienced specialist
wherever possible.
b) Treatment:
(i) Endotracheal intubation and artificial respira-
tory management64: Conduct endotracheal intubation
according to the routine procedures. Immediately
connect the endotracheal tube to a volume-cycled
ventilator. Adjust the ventilator with 100% fraction of
inspired oxygen (FIO2), 5-8 mLkg tidal volume, and
the ratio of inspiratory to expiratory phases (1 : 3 or
above). Keep the airway pressure <50 cm H2O (maxi-
mum) and <20-25 cm H2O (average). Subsequently,
set FIO2 at about 80 mmHg PaO2. Here, ensure the
maintenance of PaO2 and the prevention of baro-
trauma even if PaCO2 values are high, until exacerba-
tions improve. In principle, avoid using a ventilator at
high PEEP. The length of intubation time under me-
chanical ventilation should be minimally short.
(ii) Treatment for exacerbation: Immediately after
intubation, administer 0.3-1.0 mL of a β2 agonist or
adrenaline (0.1% before dilution), both diluted tenfold
in physiological saline, through an endotracheal tube.
Initiate and continue systemic pharmacotherapy in
the same manner as for severe asthma symptoms.
For symptoms refractory to pharmacotherapy, gen-
eral anesthesia using a narcotic (isoflurane, sevoflu-
rane, enflurane, etc.), which has a bronchodilator ac-
tion, is effective in airway relaxation.
(Note: We should avoid using halothane, because
halothane may cause ventricular arrhythmia when
combined with β2 agonists or aminophylline.)
(iii) Conditions for discontinuation: Extubate the
patient when consciousness is restored and maxi-
mum airway pressure is reduced to 20 cm H2O or be-
low by spontaneous respiration without assisted res-
piration.
4.2.4. Conditions for Hospitalization
Consider hospitalizing a patient with symptoms that
are not improved within several hours after the initia-
tion of treatment (Table 25). Immediately hospitalize
a patient with serious symptoms to conduct a more
potent treatment.
4.2.5. Conditions for Entering ICU
Consider asthma treatment in ICU or consult to a
specialist experienced in asthma treatment in the fol-
lowing situations (Table 26).
4.2.6. Conditions for Allowing a Patient to Go
Home from an Emergency Room
Airway obstruction remits and PEF recovers to80%
of the predicted value or the best value. Allow a pa-
tient to go home if symptoms are stable for 60 min or
longer after the last use of a bronchodilator. Attention
should be paid to the following points before allowing
a patient to go home (Table 27).
4.2.7. Conditions for Discharge from Hospital
It is important to educate patients who experienced
severe exacerbations, which required hospitalization,
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Table　25　Conditions requiring hospitalization
- Moderate symptoms (60-80% %PEF), insufficiently responsive to 2- to 4-h treatment (≤70% %PEF) or nonresponsive to 1- to 
2-h treatment
- Severe symptoms (<60% %PEF) nonresponsive to treatment within 1 h
- History of severe asthma attack requiring hospitalization
- Chronic symptoms that had continued for a long period (several days to 1 week) until emergency visit
- Difficulties in consulting a medical institution, e.g., heavy traffic when returning home
- Mental disorders or communication difficulties
- Complications, such as pneumonia, atelectasis, and pneumothorax
Table　26　Conditions for admission to ICU
- No response to initial treatment in an emergency room
- Symptoms suggesting risks of confusion, respiratory arrest, 
and unconsciousness
- Imminent respiratory arrest: ≥45 mmHg PaCO2 continues 
(however, respiratory insufficiency may occur regardless of 
PaCO2 level)
about high risks of death from asthma and provide
consistent instructions after discharge. Adequately
treat a patient with repeated exacerbations consider-
ing psychological and social factors. Check that
symptoms were not exacerbated for 12 or 24 h or
longer after treatment before discharge from hospi-
tal. See the following conditions (Table 28).
5. CONDITIONS FOR REFERRAL TO A SPE-
CIALIST
Asthma is a complicated disease, caused by various
external and physical factors. When there is a prob-
lem with diagnosis or treatment in long-term manage-
ment, refer the patient to a specialist based on hospi-
tal and clinic cooperation.
6. SPECIFIC CONSIDERATIONS
6.1. ALLERGIC RHINITIS (NASAL ALLERGY)
The lower respiratory tract is connected to bronchus
and the upper respiratory tract including the nose
and paranasal sinuses, thereby influencing each
other. Thus, a concept of “one airway, one disease”
has been proposed.
In Japan, about 50% of child patients with asthma
and 44-68% of adult counterparts are complicated by
allergic rhinitis. On the other hand, 15.3% of child pa-
tients with allergic rhinitis and 7.1% of adult counter-
parts are complicated by asthma. Allergic rhinitis, as
an upper respiratory tract disease and asthma, as a
lower respiratory tract disease often have a similar
pathophysiological condition as airway allergy. How-
ever, they greatly differ from each other in details.
Cedar pollen allergy is rarely complicated by asthma.
In patients with asthma complicated by allergic
rhinitis, pharmacotherapy for rhinitis, such as topical
steroid, may alleviate asthma symptoms and improve
airway hyperresponsiveness. Allergen-specific immu-
notherapy for allergic rhinitis may prevent the onset
of asthma. In addition, an LTRA improves the clinical
symptoms of patients with allergic rhinitis and
asthma. Concomitant use of an LTRA is more effec-
tive in improving airway obstruction due to asthma
than doubling the dose of an inhaled corticosteroid.65
6.2. NASAL POLYPS
Asthma is frequently complicated by nasal polyps,
and nasal polyps are more frequently complicated by
asthma. Nasal polyps are more common among
males. However, nasal polyp complicated by asthma
is twice as frequent among females than among
males. Nasal polyp, asthma, and aspirin sensitivity are
common complications. Typically, nasal symptoms
occur first, followed by nasal polyps, asthma, and as-
pirin sensitivity.
The effects of treating nasal polyps (intranasal ster-
oid and surgery of the nasal cavity) on asthma symp-
toms and respiratory function are unclear.
6.3. SINUSITIS
The association of asthma with chronic sinusitis is
known for a long time, and sinusitis has recently at-
tracted attention in association with sinobronchial
syndrome and intractable asthma. 40-60% of patients
with asthma show abnormal findings in the paranasal
sinuses on X-ray image. In general, chronic sinusitis
often precedes asthma. However, they may occur si-
multaneously. It is unclear whether sinusitis causes
asthma. However, several hypotheses (neural reflex,
infection, β-adrenergic blockade, etc.) have been sug-
gested. Asthma symptoms and respiratory function
may be improved by surgery of sinusitis.66 Intractable
chronic sinusitis, refractory to surgery and macrolide
therapy, is frequently complicated by asthma with
marked eosinophilic infiltration in the paranasal si-
nuses.
6.4. COPD
COPD is an important coexisting disease, requiring
caution in differential diagnosis in the elderly with
asthma. The pathophysiological features of asthma
are eosinophil predominant inflammation from the
center to peripheral airway, and are characterized by
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Table　27　Conditions for allowing a patient to go home from an emergency room
- Identify and avoid the causes of exacerbation.
- Consult a physician as soon as possible after going home. Inform that continuous outpatient treatment is required until PEF re-
turns to around the best value. In addition, examine the appropriateness of daily long-term treatment.
- Prescribe agents for 3-5 days when the patient goes home. Optionally, oral corticosteroids, as well as bronchodilators, are of-
ten needed.
- Check whether a patient has no trouble inhaling an inhalant or using a PEF meter adequately.
- Check whether a patient or his/her family has any problem with measures against exacerbation. It is particularly important to 
explain medicines and self-management in detail, to recognize the signs of exacerbation, immediately initiate treatment, and 
visit a medical institution.
Table　28　Conditions for discharge
- No need of inhaling a bronchodilator at ≤4-h intervals
- No short breath in walking
- No wake-up due to exacerbation at night or in the early 
morning
- (Almost) No abnormal physical fi ndings
- PEF or FEV1 is ≥80% of predicted values. Diurnal variation 
is <20%.
- Normal PaO2 value
- No trouble handling an inhaler. No trouble handling a spac-
er
- Appropriate actions against exacerbation.
- Patients understand conditions for discharge and prescrip-
tion.
- Creation of a treatment plan after discharge
reversible airway obstruction. On the other hand, in
COPD, neutrophil predominant inflammation, and
structural alterations, located at the peripheral airway
and capillary vessels of the alveoli, are noted. In
COPD, airway obstruction is caused by the combina-
tion of peripheral airway and emphysematous lesions.
Thus, differential diagnosis based on clinical symp-
toms is often difficult, although their pathophysiologi-
cal characteristics differ from each other. Some re-
ports describe that as high as 24.7% (18.4-31.7%) of
elderly patients aged 65 and over actually have both
diseases. Particularly, elderly patients with asthma,
who have a smoking history, should be diagnosed
and treated considering possible COPD complication.
In diagnosis, asthma is suspected if dyspnea, wheez-
ing, and cough occur at night or in the early morning,
while COPD is more likely if dyspnea occurs during
physical exertion. However, it is often difficult to
make a definite diagnosis based on clinical symptoms
alone. Definite diagnosis of asthma can be made if
respiratory function improves and normalized after β2
agonist inhalation. If it is reversible, but not normal-
ized, or patient response is insufficient, consider co-
existing COPD. The first step of treatment is to en-
courage smoking cessation regardless of age. Since
long-acting inhaled anticholinergics are recom-
mended for COPD, concomitant use of inhaled tiotro-
pium is preferable in elderly patients with asthma
complicated by COPD. Choose a therapeutic agent
considering that a combination inhaler device of a
corticosteroid (fluticasone) and a LABA (salmeterol)
is also effective for COPD.67 In Japan, a combination
device containing 250 μg of fluticasone is applied for
COPD.
6.5. ASPIRIN INDUCED ASTHMA
About 10% of patients with adult asthma suffer from
an asthma attack immediately or within 1 h after the
oral administration, injection, or suppository admini-
stration of nonsteroidal antiinflammatory drugs
(NSAIDs), having aspirin-like effects. Some patients
suffer from exacerbations so severe to develop im-
paired consciousness or fatality. NSAID-containing
patches, ointments, and eye drops also induce gener-
ally mild and delayed exacerbations. Watery rhinor-
rhea and nasal congestion often occur as prodromal
symptoms that may be accompanied by facial flush-
ing, conjunctival hyperemia, and digestive symptoms
(abdominal pain, diarrhea, etc.). Aside from aspirin,
almost all immunologically non-cross-reactive acid
NSAIDs (indomethacin, ibuprofen, tolmetin, fenopro-
fen, naproxen, diclofenac, ketoprofen, piroxicum, me-
fenamic acid, sulpyrine, etc.) induce asthma.68 Thus,
an arachidonate cyclooxygenase inhibitory action
(COX, especially COX-1 inhibitory action is known as
prostaglandin biosynthesis inhibitory action), a com-
mon pharmacological action of these drugs, may trig-
ger airway obstruction. This type of asthma is gener-
ally called aspirin induced asthma (aspirin-sensitive
asthma, aspirin-exacerbated respiratory disease,
etc.). However, it should be noted that aspirin is not
the only inducer.
Although rare in children, aspirin induced asthma
is more common after adolescence and most com-
mon in 30-50 year old adults. Such patients without
definite diagnosis are often seen in severe intractable
cases. Complications, including chronic rhinitis,
chronic sinusitis, impaired sense of smell, and nasal
polyps, are common, providing a clue to exact diagno-
sis.69 An additional complication is eosinophilic otitis
media. While serum IgE levels are generally low,
high levels of serum IgE are seen in about 20% of pa-
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Table　29　Agents that can be used for asthma during pregnancy and precautions for their use
Inhalants
1. Inhaled corticosteroid†
2. Inhaled β2 agonist (including a combination inhaler with an inhaled corticosteroid)‡
3. Disodium cromoglycate (DSCG)
4. Inhaled anticholinergic§
Oral medicine
1. Theophylline sustained-release preparation
2. Oral β2 agonist
3. Oral corticosteroid¶
4. Leukotriene receptor antagonist‖
5. Antihistamine‖
Injections
1. Steroid¶
2. Aminophylline
3. Adrenaline (0.1%)#
Others
Patch-type β2 agonist: Tulobuterol††
†Safety of budesonide in humans has been demonstrated in great detail.
‡There is less evidence of the safety of long-acting inhaled β2 agonist (LABA) than those of short-acting inhaled β2 agonist (SABA). 
However, these agents are almost comparable in their safety during pregnancy.
§There is no evidence of safety as a long-term management agent used during pregnancy. Safety as a reliever agent has been 
demonstrated.
¶Prednisolone and methylprednisolone do not appreciably pass through the placenta.
‖Can be administered during pregnancy only when the advantages outweigh the disadvantages. Have few risks even if unknowingly ad-
ministered during pregnancy.
#Use the subcutaneous injection of adrenaline only when inevitable. Generally avoid injection to pregnant women.
††Safe as an inhalant or oral medicine. More evidences are required.
tients, complicated by predisposition to atopy. In di-
agnosis, it is important to obtain a detailed history af-
ter undestanding the above clinical picture of NSAID-
induced asthma.
Some patients may be sensitive to food and drug
additives, such as Food Yellow No. 4 (tartrazine), so-
dium benzoate, paraben, and sulfite.69 For long-term
management, it is important to avoid the intake of
these substances, including NSAIDs, which may in-
duce exacerbation. Long-term management plan does
not differ from that for general asthma. LTRAs are
similarly effective for general asthma. In treating
acute exacerbations, caution should be exercised for
the rapid intravenous infusion of steroid succinate es-
ters (Solu-cortefⓇ, SaxizonⓇ, water-soluble Pre-
donineⓇ, Solu-MedrolⓇ, etc.) because they may exac-
erbate or induce asthma.58 If aspirin induced asthma
is suspected, intravenous infusion of steroid phos-
phate esters (DecadronⓇ, RinderonⓇ, HydrocortonⓇ,
etc.) is recommended. Oral steroids can be safely
used because of their non-ester structures. Aceta-
minophen is reportedly safe. However, caution
should be exercised because it induces exacerbation
when used in a high dose (1,000 mg). Celecoxib, a
selective COX-2 inhibitor, can be safely administered
at usual doses for aspirin induced asthma. In addi-
tion, basic anti-inflammatory analgesics (epirizole and
emorfazone), morphine, pentazocine, anticonvul-
sants, etc., can be safely administered.
6.6. PREGNANCY
6.6.1. Influences of Bronchial Asthma on Preg-
nancy and Birth
An asthma attack accompanied by airway obstruction
tends to cause hypoxemia in fetuses, posing risks of
miscarriage, increased prematurity, and brain disor-
ders.70 In fact, premature delivery, low birth weight,
and malformation are more common among patients
with asthma. However, appropriate management of
asthma can efficiently suppress the risk of death of
mother and fetus. Asthma causes no severe exacerba-
tions when well controlled before delivery. In addi-
tion, asthma symptoms and airway hyperresponsive-
ness improve in late gestation, especially at 37-40
weeks. After birth, asthma status and airway hyper-
sensitivity will be almost the same as those before
pregnancy.71
6.6.2. Influences of Antiasthmatics on Preg-
nancy and Birth
There is little evidence of teratogenicity for most anti-
asthmatic drugs (Table 29). There have been no re-
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ports associating cleft palate and systemic high-dose
steroid administration in humans. Since steroids do
not readily pass through the placenta, their serum
levels in fetuses are much lower than levels in moth-
ers, thus reducing the risk of adrenal suppression. To
gain control of severe asthma, which causes fetal hy-
poxia and harms the mother’s health, do not hesitate
to administer a systemic steroid, although too long
administration should be avoided wherever possible.
Inhaled corticosteroids are highly safe to mother and
fetus. There are no reports on teratogenicity of either
inhaled or oral β2 agonists tulobuterol, and they are
considered safe during pregnancy. Since a patch-type
β2 agonist is still a new drug form, put on the market
only in Japan and South Korea, there is no evidence
of their safety when used during pregnancy. How-
ever, patches are regarded as safe, since oral and in-
haled forms (not on the market now) of tulobuterol
are considered to be safe. There is no report on the
teratogenicity of both oral and intravenous theophyl-
line, suggesting its usefulness in controlling asthma
during pregnancy. Since the infant’s degradative rate
of theophylline is slow, caution should be exercised
in administering it to infants during lactation. Of al-
lergy drugs, DSCG is safe. Since there is not enough
evidence of the safety of LTRAs in humans, they
should be administered during pregnancy only when
the advantages outweigh the disadvantages. There
seems little teratogenicity for classic antihistamines
and relatively early-generational antiallergics (epinas-
tine, emedastine, ketotifen, tazanolast, pemirolast,
azelastine, tranilast, etc.). However, they should be
administered during pregnancy only when the advan-
tages outweigh the disadvantages.
6.6.3. Asthma Treatment during Pregnancy
Considering the risks of asthma attack on fetuses and
pregnant women, it is more beneficial to continue to
treat patients with asthma during pregnancy. Appro-
priate actions (agents, allergen avoidance, environ-
mental management, smoking cessation, and separa-
tion of smoking areas, rest of mind and body, etc.)
should be taken against exacerbating factors to pre-
vent symptoms and maintain respiratory function. In-
haled corticosteroids are recommended as first-line
therapy for long-term management. If an inhaled cor-
ticosteroid alone is not enough effective, add a long-
acting inhaled β2 agonist, theophylline sustained-
release preparation, patch-type β2 agonist, etc. Con-
sider LTRAs when the advantages outweigh the dis-
advantages.
Allergen-specific immunotherapy (hyposensitiza-
tion) can be continued during pregnancy if initiated
before pregnancy. However, do not initiate the ther-
apy during pregnancy. Continue the administration of
anti-IgE antibody only when the advantages outweigh
the disadvantages, because of the lack of information
on anti-IgE antibody during pregnancy.
To treat exacerbations, administer a short-acting
inhaled β2 agonist. If the effects are insufficient, use
oral medicine or injection (steroids and intravenous
infusion of aminophylline). Oxygen inhalation is rec-
ommended to prevent fetal hypoxemia. Complica-
tions, such as abortion and premature delivery, pre-
mature rupture of the membranes, albuminuria, and
eclampsia, are more common among patients with
asthma. Certain congenital disorders (malformation)
are seen in 2-4% of normal pregnancies. These com-
plications should be explained in detail before admini-
stration to obtain patient’s trust. In addition, smoking,
including passive smoking, has more serious influ-
ences than any agents clinically used for mother and
fetus do. This must be emphasized to patients, their
spouses, and people around the patients to under-
stand the necessity of smoking cessation.72
6.7. COUGH VARIANT ASTHMA
In Japan, chronic cough is caused by cough variant
asthma (36%), atopic cough (16%), sinobronchial syn-
drome (16%), postinfectious cough (2%), and gastroe-
sophageal reflux disease (2%),73 with cough variant
asthma, atopic cough, and sinobronchial syndrome
being the three major causes. In contrast, in Europe
and the United States, cough variant asthma, postna-
sal drip and rhinitis, and gastroesophageal reflux dis-
ease are the three major causes.74
Cough variant asthma is distinguished from
asthma by the lack of wheezing. Cough variant
asthma belongs to the subgroup of asthma or inter-
mediate asthma and is similar to asthma in the follow-
ing points: (i) airway hyperresponsiveness is mildly
present (intermediate between patients with mild
asthma and healthy individuals)75; (ii) cough sensitiv-
ity is within a normal range; (iii) atopic state is com-
mon; (iv) eosinophils are noted in sputum or induced
sputum; (v) eosinophilic infiltration is noted in the
bronchial mucosa; (vi) eosinophils are increased in
bronchoalveolar lavage fluid (BALF); (vii) fraction of
exhaled nitric oxide (FeNO) is increased; and (viii)
inhaled or oral corticosteroids are effective. Bron-
chodilators, including β2 agonists, are effective.
Cough variant asthma is not usually accompanied by
sputum, is more severe at bedtime, during the night
and early morning, and is induced by cold and warm
air, passive smoking, conversation, exercise, alcohol,
mental stress, etc. About 30% of patients with cough
variant asthma develop wheezing asthma. Since
cough can be prevented with an inhaled corticoster-
oid, long-term management with an inhaled corti-
costeroid is recommended.
Atopic cough is similar to “non-asthmatic eosino-
philic bronchitis” in Europe and the United States.74
Atopic cough is somewhat similar to cough variant
asthma in clinical symptoms, and shows the following
features: (i) there is atopic state, (ii) bronchodilators
such as β2 agonists are ineffective, (iii) there is no air-
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way hyperresponsiveness, (iv) cough sensitivity is in-
creased, (v) H1 antagonists and steroids are effective,
and (vi) asthma does not develop. Long-term man-
agement is unnecessary. In addition, unlike cough
variant asthma, FeNO does not increase. Other im-
portant diseases, differentiated from chronic non-
productive cough, include cough caused by postnasal
drip, gastroesophageal reflux, or angiotensin convert-
ing enzyme inhibitors.
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